

uch, of the data.

\* \* \* \* \*

\* Help Desk --> 703-305-9000 \*

\* \* \* \* \*

\* The Help Desk is staffed for APS support 7 days/week. \*

\* Monday through Friday: 6:30am - 9:00pm \*

\* Saturday, Sunday, Holidays: 8:30am - 5:00 pm \*

\* \* \* \* \*

\* The Help Desk staff at this number will handle all APS \*

\* related questions. \*

\* \* \* \* \*

\* >>>>>>>>>> NEW SUNDAY HOURS !!! <<<<<<<<<<<< \*

\* \* \* \* \*

\* The APS is available: \*

\* 6:30am - 9:00pm Monday through Friday \*

\* 7:30am - 5:00pm Saturday, Sunday, Holidays \*

\* \* \* \* \*

\* APS is unavailable Thanksgiving Day, Christmas Day, \*

\* and New Year's Day. \*

\* \* \* \* \*

FILE 'USPAT' ENTERED AT 08:05:12 ON 07 MAR 1999

\* \* \* \* \*

\* W E L C O M E T O T H E \*

\* U. S. P A T E N T T E X T F I L E \*

=> e lasky/in

E#	FILE	FREQUENCY	TERM
E1	USPAT	1	LASKOWSKI, ZBIGNIEW/IN
E2	USPAT	1	LASKUS, ROLE/IN
E3	USPAT	0 -->	LASKY/IN
E4	USPAT	1	LASKY, ARTHUR J/IN
E5	USPAT	1	LASKY, BERNARD J/IN
E6	USPAT	2	LASKY, DANIEL/IN
E7	USPAT	7	LASKY, DANIEL J/IN
E8	USPAT	1	LASKY, FRED D/IN
E9	USPAT	4	LASKY, HAROLD J/IN
E10	USPAT	2	LASKY, JACK S/IN
E11	USPAT	16	LASKY, JEROME B/IN
E12	USPAT	1	LASKY, JEROME BRET/IN

=> e

E13	USPAT	1	LASKY, JOHN C/IN
E14	USPAT	1	LASKY, JOHN J JR/IN
E15	USPAT	18	LASKY, LAURENCE A/IN
E16	USPAT	1	LASKY, MAX/IN
E17	USPAT	1	LASKY, MERVYN C/IN
E18	USPAT	1	LASKY, MICHAEL BARRY/IN
E19	USPAT	1	LASKY, MICHAEL S/IN
E20	USPAT	3	LASKY, RICHARD J/IN
E21	USPAT	1	LASKY, ROBERT/IN
E22	USPAT	1	LASKY, RONALD C/IN
E23	USPAT	2	LASKY, RONALD J/IN
E24	USPAT	1	LASKY, SEGISMUNDO NATES/IN

=>s e15

L3 18 "LASKY, LAURENCE A"/IN

=> d l3 1-18 date

L3: 1 of 18

TITLE: Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use

US PAT NO: 5,853,978 DATE ISSUED: Dec. 29, 1998

[IMAGE AVAILABLE]

APPL-NO: 08/282,857 DATE FILED: Jul. 29, 1994

REL-US-DATA: Continuation of Ser. No. 129,009, Sep. 29, 1993, abandoned, which is a continuation of Ser. No. 979,391, Nov. 19, 1992, abandoned, which is a continuation of Ser. No. 227,568, Aug. 2, 1988, abandoned, which is a division of Ser. No. 861,016, May 8, 1986, abandoned, which is a continuation-in-part of Ser. No. 805,069, Dec. 4, 1985, abandoned, which is a continuation-in-part of Ser. No. 685,272, Dec. 24, 1987, abandoned.

L3: 2 of 18

TITLE: Vaccine based on membrane bound proteins and process for making them

US PAT NO: 5,851,533 DATE ISSUED: Dec. 22, 1998

APPL-NO: [IMAGE AVAILABLE]  
08/35,084 DATE FILED: Dec. 15, 1994  
REL-US-DATA: Continuation of Ser. No. 171,858, Dec. 11, 1993,  
abandoned, which is a continuation of Ser. No. 814,243,  
Dec. 23, 1991, which is a continuation of Ser. No.  
695,585, May 3, 1991, abandoned, which is a continuation  
of Ser. No. 878,087, Jun. 24, 1986, abandoned, which is  
a continuation of Ser. No. 588,170, Mar. 9, 1984,  
abandoned, which is a continuation-in-part of Ser. No.  
527,917, Aug. 30, 1983, abandoned, and Ser. No. 547,551,  
Oct. 31, 1983, abandoned.

L3: 3 of 18

TITLE: Soluble lymphocyte homing receptors  
US PAT NO: 5,840,844 DATE ISSUED: Nov. 24, 1998  
[IMAGE AVAILABLE]  
APPL-NO: 08/513,278 DATE FILED: Aug. 10, 1995  
REL-US-DATA: Continuation of Ser. No. 59,029, May 6, 1993, abandoned,  
which is a continuation of Ser. No. 786,149, Oct. 31,  
1991, Pat. No. 5,216,131, which is a division of Ser.  
No. 315,015, Feb. 23, 1989, Pat. No. 5,098,833.

L3: 4 of 18

TITLE: .kappa./.mu.-like protein tyrosine phosphatase, PTP  
.lambda.  
US PAT NO: 5,814,507 DATE ISSUED: Sep. 29, 1998  
[IMAGE AVAILABLE]  
APPL-NO: 08/652,971 DATE FILED: May 24, 1996

L3: 5 of 18

TITLE: Hybrid immunoglobulins  
US PAT NO: 5,714,147 DATE ISSUED: Feb. 3, 1998  
[IMAGE AVAILABLE]  
APPL-NO: 08/451,848 DATE FILED: May 26, 1995  
REL-US-DATA: Continuation of Ser. No. 185,670, Jan. 21, 1994, Pat. No.  
5,514,582, which is a continuation of Ser. No. 986,931,  
Dec. 8, 1992, Pat. No. 5,428,130, which is a  
continuation of Ser. No. 808,122, Dec. 19, 1991, Pat.  
No. 5,225,538, which is a division of Ser. No. 440,625,  
Nov. 22, 1989, Pat. No. 5,116,964, which is a  
continuation-in-part of Ser. No. 315,015, Feb. 23, 1989,  
Pat. No. 5,098,853.

L3: 6 of 18

TITLE: Method of hybridization using oligonucleotide probes  
US PAT NO: 5,654,147 DATE ISSUED: Aug. 5, 1997  
[IMAGE AVAILABLE]  
APPL-NO: 08/447,486 DATE FILED: May 23, 1995  
REL-US-DATA: Continuation of Ser. No. 829,867, Feb. 3, 1992, Pat. No.  
5,618,789, which is a division of Ser. No. 570,096, Aug.  
20, 1990, Pat. No. 5,618,788, which is a continuation of  
Ser. No. 83,758, Aug. 7, 1987, Pat. No. 4,965,199, which  
is a continuation of Ser. No. 602,312, Apr. 20, 1984,  
abandoned.

L3: 7 of 18

TITLE: Method for purification of L-selectin ligands  
US PAT NO: 5,652,343 DATE ISSUED: Jul. 29, 1997  
[IMAGE AVAILABLE]  
APPL-NO: 08/294,675 DATE FILED: Aug. 23, 1994  
REL-US-DATA: Continuation of Ser. No. 18,994, Feb. 18, 1993, Pat. No.  
5,484,891, which is a continuation of Ser. No. 834,902,  
Feb. 13, 1993, Pat. No. 5,304,640, which is a  
continuation-in-part of Ser. No. 695,805, May 6, 1991,  
Pat. No. 5,318,890.

TITLE: Selected variants  
 US PAT NO: 5,593,882 DATE ISSUED: Jan. 14, 1997  
 [IMAGE AVAILABLE]  
 APPL-NO: 08/274,661 DATE FILED: Jul. 13, 1994  
 REL-US-DATA: Continuation of Ser. No. 956,701, Oct. 1, 1992, abandoned,  
 which is a continuation-in-part of Ser. No. 879,036,  
 Apr. 30, 1992, abandoned.

TITLE: Recombinant DNA encoding hybrid immunoglobulins  
 US PAT NO: 5,514,582 DATE ISSUED: May 7, 1996  
 [IMAGE AVAILABLE]  
 APPL-NO: 08/185,670 DATE FILED: Jan. 21, 1994  
 REL-US-DATA: Continuation of Ser. No. 986,931, Dec. 8, 1992, Pat. No.  
 5,428,130, which is a continuation of Ser. No. 808,122,  
 Dec. 16, 1991, Pat. No. 5,225,538, which is a division  
 of Ser. No. 440,625, Nov. 22, 1989, Pat. No. 5,116,964,  
 which is a continuation-in-part of Ser. No. 315,015,  
 Feb. 23, 1989, Pat. No. 5,098,833.

TITLE: Selectin ligands  
 US PAT NO: 5,484,891 DATE ISSUED: Jan. 16, 1996  
 [IMAGE AVAILABLE]  
 APPL-NO: 08/018,994 DATE FILED: Feb. 18, 1993  
 REL-US-DATA: Division of Ser. No. 834,902, Feb. 13, 1992, Pat. No.  
 5,304,640, which is a continuation-in-part of Ser. No.  
 695,805, May 6, 1991, Pat. No. 5,318,890.

TITLE: Expression vector encoding hybrid immunoglobulins  
 US PAT NO: 5,455,165 DATE ISSUED: Oct. 3, 1995  
 [IMAGE AVAILABLE] DISCL-DATE: May 26, 2009  
 APPL-NO: 08/185,669 DATE FILED: Jan. 21, 1994  
 REL-US-DATA: Continuation of Ser. No. 986,931, Dec. 8, 1992, which is a  
 continuation of Ser. No. 808,122, Dec. 16, 1991, Pat.  
 No. 5,225,538, which is a division of Ser. No. 440,625,  
 Nov. 22, 1989, Pat. No. 5,116,964, which is a  
 continuation-in-part of Ser. No. 315,015, Feb. 23, 1989,  
 Pat. No. 5,098,833.

TITLE: Hybrid immunoglobulins  
 US PAT NO: 5,428,130 DATE ISSUED: Jun. 27, 1995  
 [IMAGE AVAILABLE] DISCL-DATE: May 26, 2009  
 APPL-NO: 07/986,931 DATE FILED: Dec. 8, 1992  
 REL-US-DATA: Continuation of Ser. No. 808,122, Dec. 16, 1991, Pat. No.  
 5,225,538, which is a continuation of Ser. No. 440,625,  
 Nov. 22, 1989, Pat. No. 5,116,964, which is a  
 continuation-in-part of Ser. No. 315,015, Feb. 23, 1989,  
 Pat. No. 5,098,833.

TITLE: DNA sequence encoding a selectin ligand  
 US PAT NO: 5,304,640 DATE ISSUED: Apr. 19, 1994  
 [IMAGE AVAILABLE]  
 APPL-NO: 07/834,902 DATE FILED: Feb. 13, 1992  
 REL-US-DATA: Continuation-in-part of Ser. No. 695,805, May 6, 1991.

TITLE: Lymphocyte homing receptor/immunoglobulin fusion proteins  
 US PAT NO: 5,225,538 DATE ISSUED: Jul. 6, 1993  
 [IMAGE AVAILABLE]

APPL-NO: 07/808,122 DATE FILED: Dec. 16, 1991  
REL-US-DATA: Division of Ser. No. 440,625, Nov. 22, 1989, Pat. No.  
5,116,964, which is a continuation of Ser. No. 315,015,  
Feb. 23, 1989, Pat. No. 5,098,833.

L3: 15 of 18

TITLE: Lymphocyte homing receptors  
US PAT NO: 5,216,131 DATE ISSUED: Jun. 1, 1993  
[IMAGE AVAILABLE]  
APPL-NO: 07/786,149 DATE FILED: Oct. 31, 1991  
REL-US-DATA: Division of Ser. No. 315,015, Feb. 23, 1989, Pat. No.  
5,098,833.

L3: 16 of 18

TITLE: Hybrid immunoglobulins  
US PAT NO: 5,116,964 DATE ISSUED: May 26, 1992  
[IMAGE AVAILABLE]  
APPL-NO: 07/440,625 DATE FILED: Nov. 22, 1989  
REL-US-DATA: Continuation-in-part of Ser. No. 315,015, Feb. 23, 1989.

L3: 17 of 18

TITLE: DNA sequence encoding a functional domain of a lymphocyte  
homing receptor  
US PAT NO: 5,098,833 DATE ISSUED: Mar. 24, 1992  
[IMAGE AVAILABLE]  
APPL-NO: 07/315,015 DATE FILED: Feb. 23, 1989

L3: 18 of 18

TITLE: Molecularly cloned diagnostic product and method of use  
US PAT NO: 4,855,224 DATE ISSUED: Aug. 8, 1989  
[IMAGE AVAILABLE]  
APPL-NO: 06/776,059 DATE FILED: Sep. 13, 1985  
REL-US-DATA: Continuation of Ser. No. 587,763, Mar. 9, 1984, abandoned,  
which is a continuation-in-part of Ser. No. 527,916,  
Aug. 30, 1983, abandoned, and a continuation-in-part of  
Ser. No. 547,552, Oct. 31, 1983, abandoned.

=> s (l(w)selectin?) (P) (cd34)

562727 L  
216693 SELECTIN?  
324 CD34

L4 8 (L(W)SELECTIN?) (P) (CD34)

=> d 14 1-8 date

L4: 1 of 8

TITLE: Human trk receptors and neurotrophic factor inhibitors  
US PAT NO: 5,877,016 DATE ISSUED: Mar. 2, 1999  
[IMAGE AVAILABLE]  
APPL-NO: 08/286,846 DATE FILED: Aug. 5, 1994  
REL-US-DATA: Continuation-in-part of Ser. No. 215,139, Mar. 18, 1994,  
abandoned.

L4: 2 of 8

TITLE: Human TRK receptors and neurotrophic factor inhibitors  
US PAT NO: 5,844,092 DATE ISSUED: Dec. 1, 1998  
[IMAGE AVAILABLE]  
APPL-NO: 08/359,705 DATE FILED: Dec. 20, 1994  
REL-US-DATA: Continuation-in-part of Ser. No. 286,846, Aug. 5, 1994,  
which is a continuation-in-part of Ser. No. 215,139,  
Mar. 18, 1994, abandoned.

L4: 3 of 8

TITLE: Methods for synthesizing sulfated disaccharide inhibitors  
of lectins  
US PAT NO: 5,783,993 DATE ISSUED: Jul. 21, 1998  
[IMAGE AVAILABLE]  
APPL-NO: 08/518,381 DATE FILED: Aug. 23, 1995  
REL-US-DATA: Continuation-in-part of Ser. No. 432,849, May 2, 1995,  
Pat. No. 5,489,578, which is a continuation of Ser. No.  
155,947, Nov. 10, 1993, abandoned.

L4: 4 of 8

TITLE: Treating inflammation via the administration of specific  
sulfatase enzymes and/or sulfation inhibitor  
US PAT NO: 5,695,752 DATE ISSUED: Dec. 9, 1997  
[IMAGE AVAILABLE]  
APPL-NO: 08/496,857 DATE FILED: Jun. 30, 1995  
REL-US-DATA: Continuation of Ser. No. 214,947, Mar. 16, 1994,  
abandoned, which is a continuation-in-part of Ser. No.  
943,817, Sep. 11, 1992, abandoned, and Ser. No. 155,947,  
Nov. 19, 1993, abandoned.

L4: 5 of 8

TITLE: Human breast carcinoma cell line capable of production of  
a spontaneously metastasizing tumor in animals for use  
in anticancer drug testing  
US PAT NO: 5,693,533 DATE ISSUED: Dec. 2, 1997  
[IMAGE AVAILABLE]  
APPL-NO: 08/350,938 DATE FILED: Dec. 7, 1994

L4: 6 of 8

TITLE: Mocarhagin, a cobra venom protease, and therapeutic uses  
thereof  
US PAT NO: 5,659,018 DATE ISSUED: Aug. 19, 1997  
[IMAGE AVAILABLE]  
APPL-NO: 08/520,977 DATE FILED: Aug. 1, 1995

L4: 7 of 8

TITLE: Sulfated ligands for l-selectin and methods of treating  
inflammation  
US PAT NO: 5,489,578 DATE ISSUED: Feb. 6, 1996  
[IMAGE AVAILABLE]  
APPL-NO: 08/432,849 DATE FILED: May 2, 1996  
REL-US-DATA: Continuation of Ser. No. 155,947, Nov. 19, 1993,  
abandoned.

L4: 8 of 8

TITLE: Sulfatides as anti-inflammatory compounds  
US PAT NO: 5,486,536 DATE ISSUED: Jan. 23, 1996  
[IMAGE AVAILABLE]  
APPL-NO: 08/289,585 DATE FILED: Aug. 15, 1994

begin 5,73,155,399,357

15jan00 14:33:56 User208760 Session D1416.3  
\$0.71 0.121 DialUnits File652  
\$0.71 Estimated cost File652  
\$1.19 0.201 DialUnits File653  
\$1.19 Estimated cost File653  
\$6.58 1.115 DialUnits File654  
\$12.35 19 Type(s) in Format 3  
\$0.00 19 Type(s) in Format 95 (KWIC)  
\$12.35 38 Types  
\$18.93 Estimated cost File654  
OneSearch, 3 files, 1.437 DialUnits FileOS  
\$0.20 TYMNET  
\$21.03 Estimated cost this search  
\$21.44 Estimated total session cost 1.586 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2000/Dec W2  
(c) 2000 BIOSIS

File 73:EMBASE 1974-2000/Jan W1  
(c) 2000 Elsevier Science B.V.

File 155:MEDLINE(R) 1966-2000/Mar W2  
(c) format only 2000 Dialog Corporation

File 399:CA SEARCH(R) 1967-2000/UD=13203  
(c) 2000 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.  
RANK charge added; see HELP RATES 399.

File 357:Derwent Biotechnology Abs 1982-2000/Jan B1  
(c) 2000 Derwent Publ Ltd

\*File 357: Derwent changes DialUnit pricing from May 1, 1999. See  
HELP DERWENT for details.

Set Items Description

? s (l(w)selectin)(40n)(cd34)

1531343 L  
19423 SELECTIN  
19586 CD34

S1 182 (L(W)SELECTIN)(40N)(CD34)  
? s 1(40n)(inhibit? or suppress? or antagoni? or decreas?)(inflamm? or  
autoimmun?)

>>>Invalid syntax

? s 1(40n)(inhibit? or suppress? or antagoni? or decreas?)(30n)(inflamm? or  
autoimmun?)

Processing  
Processing

7186114 1  
3026099 INHIBIT?  
592501 SUPPRESS?  
802627 ANTAGONI?  
2134564 DECREAS?  
560055 INFLAMM?  
154178 AUTOIMMUN?  
S2 34158 1(40N)(INHIBIT? OR SUPPRESS? OR ANTAGONI? OR  
DECREAS?)(30N)(INFLAMM? OR AUTOIMMUN?)

? s s1(40n)(inhibit? or suppress? or antagoni? or decreas?)(30n)(inflamm? or  
autoimmun?)

Processing

```
      182  S1
3026099  INHIBIT?
592501   SUPPRESS?
802627   ANTAGONI?
2134564   DECREAS?
560055   INFLAMM?
154178   AUTOIMMUN?
S3        6  S1(40N)(INHIBIT? OR SUPPRESS? OR ANTAGONI? OR
              DECREAS?)(30N)(INFLAMM? OR AUTOIMMUN?)
```

? rd s3

...completed examining records

```
      S4        3  RD S3 (unique items)
```

? t s4/7/all

4/7/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

10337139 BIOSIS NO.: 199698792057

CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein.

AUTHOR: Suzuki Akira(a); Andrew David P; Gonzalo Jose-Angel; Fukumoto Manabu; Spellberg Jason; Hashiyama Motohiro; Takimoto Hiroaki; Gerwin Nicole; Webb Iain; Molineux Graham; Amakawa Ryuichi; Tada Yoshifumi; Wakeham Andrew; Brown John; McNiece Ian; Ley Klaus; Butcher Eugene C; Suda Toshio; Gutierrez-Ramos Jose-Carlos; Mak Tak Wah

AUTHOR ADDRESS: (a)Amgen Inst., Ontario Cancer Inst., Dep. Med. Biophysics Immunol., Univ. Toronto, 620 University \*\*Canada

JOURNAL: Blood 87 (9):p3550-3562 1996

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: **CD34** is expressed on the surface of hematopoietic stem/progenitor cells, stromal cells, and on the surface of high-endothelial venules (HEV). **CD34** binds **L-selectin**, an adhesion molecule important for leukocyte rolling on venules and lymphocyte homing to peripheral lymph nodes (PLN). We generated **CD34**-deficient mutant animals through the use of homologous recombination. Wild-type and mutant animals showed no differences in lymphocyte binding to PLN HEV, in leukocyte rolling on venules or homing to PLN, in neutrophil extravasation into peritoneum in response to **inflammatory** stimulus, nor in delayed type hypersensitivity. Anti-**L-selectin** monoclonal antibody (MEL-14) also **inhibited** these immune responses similarly in both **CD34**-deficient and wild-type mice. However, eosinophil accumulation in the lung after inhalation of a model allergen, ovalbumin, is several-fold lower in mutant mice. We found no abnormalities in hematopoiesis in adult mice and interactions between mutant progenitor cells and a stromal cell line in vitro were normal. No differences existed in the recovery of progenitor cells after 5-fluorouracil treatment, nor in the mobilization of progenitor cells after granulocyte colony-stimulating factor treatment compared with wild-type animals. Surprisingly, although **CD34** was not expressed in these mice, a portion of its 90-kD band crossreactive with MECA79 remained after Western blot. Thus, we have identified an additional molecule(s) that might be involved in leukocyte trafficking. These results indicate that **CD34** plays an important role in eosinophil trafficking into the lung.

4/7/2 (Item 2 from file: 5)



DIALOG(R)File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09590839 BIOSIS NO.: 199598045757

Sulfation-dependent recognition of high endothelial venules (HEV)-ligands  
by L-selectin and MECA 79, an adhesion-blocking monoclonal antibody.

AUTHOR: Hemmerich Stefan; Butcher Eugene C; Rosen Steven D(a)

AUTHOR ADDRESS: (a)Dep. Anat., Univ. Calif., San Francisco, CA 94143-0452\*\*  
USA

JOURNAL: Journal of Experimental Medicine 180 (6):p2219-2226 1994

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: **L-selectin** is a lectin-like receptor that mediates the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes during the process of lymphocyte recirculation. Two sulfated, mucin-like glycoproteins known as Sgp50/GlyCAM-1 and Sgp90/**CD34** have previously been identified as HEV-associated ligands for **L-selectin**. These proteins were originally detected with an **L-selectin**/Ig chimera called LEC-IgG. GlyCAM-1 and **CD34** are also recognized by an antiperipheral node addressin (PNAd) mAb called MECA 79, which blocks **L-selectin**-dependent adhesion and selectively stains lymph node HEV. The present study compares the requirements for the binding of MECA 79 and LEC-IgG to HEV-ligands. Whereas desialylation of GlyCAM-1 and **CD34** drastically reduced binding to LEC-IgG, this treatment enhanced the binding of GlyCAM-1 to MECA 79. In contrast, the binding of both MECA 79 and LEC-IgG to GlyCAM-1 and **CD34** was greatly decreased when the sulfation of these ligands was reduced with chlorate, a metabolic inhibitor of sulfation. Because MECA 79 stains HEV-like vessels at various sites of inflammation, recognition by **L-selectin** of ligands outside of secondary lymphoid organs may depend on sulfation. In addition to their reactivity with GlyCAM-1 and **CD34**, both MECA 79 and LEC-IgG recognize an independent molecule of approx 200 kD in a sulfate-dependent manner. Thus, this molecule, which we designate Sgp200, is an additional ligand for **L-selectin**.

4/7/3 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2000 Elsevier Science B.V. All rts. reserv.

05941946 EMBASE No: 1994357259

Sulfation-dependent recognition of high endothelial venules (HEV)-ligands  
by L-selectin and MECA 79, an adhesion-blocking monoclonal antibody

Hemmerich S.; Butcher E.C.; Rosen S.D.

Department of Anatomy, University of California, San Francisco, CA

94143-0452 United States

Journal of Experimental Medicine ( J. EXP. MED. ) (United States) 1994,  
180/6 (2219-2226)

CODEN: JEMEA ISSN: 0022-1007

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**L-selectin** is a lectin-like receptor that mediates the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes during the process of lymphocyte recirculation. Two sulfated, mucin-like glycoproteins known as Sgp50/GlyCAM-1 and Sgp90/**CD34** have previously been identified as HEV-associated ligands for **L-selectin**. These proteins were originally detected with an **L-selectin**/Ig chimera called LEC-IgG. GlyCAM-1 and **CD34** are also recognized by an anti-peripheral node addressin (PNAd) mAb called MECA 79, which blocks **L-selectin**-dependent adhesion and selectively stains lymph node HEV. The present study compares the requirements for the binding of MECA 79

and LEC-IgG to HEV-ligands. Whereas desialylation of GlyCAM-1 and **CD34** drastically reduced binding to LEC-IgG, this treatment enhanced the binding of GlyCAM-1 to MECA 79. In contrast, the binding of both MECA 79 and LEC-IgG to GlyCAM-1 and **CD34** was greatly decreased when the sulfation of these ligands was reduced with chlorate, a metabolic inhibitor of sulfation. Because MECA 79 stains HEV-like vessels at various sites of inflammation, recognition by **L-selectin** of ligands outside of secondary lymphoid organs may depend on sulfation. In addition to their reactivity with GlyCAM-1 and **CD34**, both MECA 79 and LEC-IgG recognize an independent molecule of ~200 kD in a sulfate-dependent manner. Thus, this molecule, which we designate Sgp200, is an additional ligand for **L-selectin**.

19586 CD34  
4316035 PROTEIN?  
250217 POLYPEPTIDE?  
3026099 INHIBIT?  
592501 SUPPRESS?  
2134564 DECREASES?  
184795 DIMINISH?  
802627 ANTAGONI?  
560055 INFLAMM?  
154178 AUTOIMMUN?  
385833 ADHESI?

S3 71 (CD34) (10N) (PROTEIN? OR POLYPEPTIDE?) (30N) (INHIBIT? OR  
SUPPRESS? OR DECREASES? OR DIMINISH? OR  
ANTAGONI?) (30N) (INFLAMM? OR AUTOIMMUN? OR ADHESI?)

? rd s3

...examined 50 records (50)

...completed examining records

S4 44 RD S3 (unique items)

? t s4/7/all

6/7/14 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

07804924 94064378

Robert Feulgen Lecture 1993. L-selectin and its biological ligands.

Rosen SD

Department of Anatomy, University of California, San Francisco  
94143-0452.

Histochemistry (GERMANY) Sep 1993, 100 (3) p185-91, ISSN 0301-5564

Journal Code: G9K

Contract/Grant No.: GM23547, GM, NIGMS

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

This review considers the leukocyte adhesive receptor known as L-selectin. This protein, belonging to the selectin family of cell-cell adhesion receptors, mediates adhesion by virtue of a C-type lectin domain at its amino terminus. The protein was discovered as a lymphocyte homing receptor involved in the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes. Its widespread distribution on all leukocyte populations underlies a more general role in a variety of leukocyte-endothelial interactions. In the HEV interaction, cognate HEV ligands for L-selectin have been identified as two sulfated, sialylated, and fucosylated glycoproteins, known as GlyCAM-1 and **Sgp90**. These ligands have mucin-like domains which confer important properties for their proposed adhesive function. The carbohydrate features of these ligands, essential for their interaction with L-selectin, are reviewed. The existence of extralymphoid ligands for L-selectin is also discussed. (75

430106 96028304

Selective modulation of the expression of L-selectin ligands by an immune response.

Hoke D; Mebius RE; Dybdal N; Dowbenko D; Gribbling P; Kyle C; Baumhueter S ; Watson SR

Department of Immunology, Genentech, South San Francisco, California 94080, USA.

Curr Biol (ENGLAND) Jun 1 1995, 5 (6) p670-8, ISSN 0960-9822

Journal Code: B44

Languages: ENGLISH

Document type: JOURNAL ARTICLE

**BACKGROUND:** The adhesion molecule L-selectin is expressed on the cell surface of lymphocytes and mediates their migration from the bloodstream into lymph nodes. L-selectin is able to recognize four glycoprotein ligands, three of which--Sgp50, **Sgp90**, and Sgp200--are sulphated, bind specifically to L-selectin and are synthesized by the high endothelial venules of the peripheral and mesenteric lymph nodes. One of these three sulphated L-selectin ligands, **Sgp90**, has been shown to be identical to the known surface marker CD34 and is expressed on the cell surface of endothelial cells. The cDNA encoding Sgp50 has been cloned, and its product, which has been designated GlyCAM-1, is secreted. The third ligand, Sgp200, is both secreted and cell-associated. We have investigated how the expression of these sulphated glycoproteins is regulated during an immune response. **RESULTS:** Here we demonstrated that, during a primary immune response, the expression and secretion of both GlyCAM-1 and Sgp200 are reduced, recovering to normal levels 7-10 days after antigen stimulation. In contrast, the expression of cell-associated CD34 and Sgp200 is relatively unaffected. These results may account for the modest decreases in the binding of an L-selectin-IgG fusion protein to high endothelial venules of inflamed peripheral lymph nodes that have been observed after antigen exposure. In vivo experiments show that, following the decrease in the levels of secreted GlyCAM-1 and Sgp200, migration of lymphocytes from the blood stream into lymph nodes remains L-selectin-dependent, but more lymphocytes home to antigen-primed than unprimed peripheral lymph nodes. **CONCLUSIONS:** We suggest that the secreted forms of the L-selectin ligands GlyCAM-1 and Sgp200 act as modulators of cell adhesion, and that cell-associated CD34 and Sgp200 are the ligands that mediate the initial loose binding of lymphocytes to high endothelial venules.

6/7/12 (Item 2 from file: 73)  
DIALOG(R) File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

05400483 EMBASE No: 1993168582

Direct demonstration of heterogeneous, sulfated O-linked carbohydrate chains on an endothelial ligand for L-selectin

Imai Y.; Rosen S.D.

Department of Chemical Toxicology, University of Tokyo, Tokyo 113 Japan  
Glycoconjugate Journal ( GLYCOCONJUGATE J. ) (United Kingdom) 1993, 10/1  
(34-39)

CODEN: GLJOE ISSN: 0282-0080

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

We have previously identified endothelial ligands for L-selectin as sialylated, fucosylated and sulfated glycoproteins of approximately 50 kDa and 90 kDa (Sgp50 and **Sgp90**). In this report, we use the beta elimination reaction to demonstrate directly the presence of sulfated O-linked sugar chains on one of these ligands, after metabolic labeling with radiolabeled sulfate or fucose. All of the sulfated and the majority of the fucosylated O-linked sugar chains were shown to be sialylated by affinity chromatography on a Limax agglutinin column. Analyses by anion exchange and gel permeation chromatography revealed a complexity of sugar chains, which were heterogeneous both in charge and size. Charged groups other than sialic acid appeared to exert a predominant influence on the total charge of the sugar chains. The probable existence of a varying number of sulfate modifications per sugar chain is discussed.

6/7/8 (Item 8 from file: 5)  
DIALOG(R) File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

07679418 BIOSIS NO.: 000092026339  
IDENTIFICATION OF A CARBOHYDRATE-BASED ENDOTHELIAL LIGAND FOR A LYMPHOCYTE  
HOMING RECEPTOR  
AUTHOR: IMAI Y; SINGER M S; FENNIE C; LASKY L A; ROSEN S D  
AUTHOR ADDRESS: DEP. ANATOMY, PROGRAM IMMUNOL., UNIVERSITY CALIF., SAN  
FRANCISCO, CALIF. 94143-0452.  
JOURNAL: J CELL BIOL 113 (5). 1991. 1213-1222.  
FULL JOURNAL NAME: Journal of Cell Biology  
CODEN: JCLBA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: Lymphocyte attachment to high endothelial venules within lymph nodes is mediated by the peripheral lymph node homing receptor (pnHR), originally defined on mouse lymphocytes by the MEL-14 mAb. The pnHR is a calcium-dependent lectin-like receptor, a member of the LEC-CAM family of adhesion proteins. Here, using a soluble recombinant form of the homing receptor, we have identified an endothelial ligand for the pnHR as an .apprx. 50-kD sulfated, fucosylated, and sialylated glycoprotein, which we designate Sgp50 (sulfated glycoprotein of 50 kD). Recombinant receptor binding to this lymph node-specific glycoprotein requires calcium and is inhibitable by specific carbohydrates and by MEL-14 mAb. Sialylation of the component is required for binding. Additionally, the glycoprotein is precipitated by MECA-79, an adhesion-blocking mAb reaction with lymph node HEV. A related glycoprotein of .apprx. 90 kD (designated as **Sgp90**) is also identified.

6/7/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08815225 BIOSIS NO.: 199395104576  
Sulphation requirement for GlyCAM-1, an endothelial ligand for L-selectin.  
AUTHOR: Imai Yasuyuki; Lasky Laurence A; Rosen Steven D(a)  
AUTHOR ADDRESS: (a)Dep. Anat., Program Immunol., Univ. Calif., San  
Francisco, CA 94143-0452\*\*USA  
JOURNAL: Nature (London) 361 (6412):p555-557 1993  
ISSN: 0028-0836  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: L-selectin participates in the initial attachment of leukocytes to the vascular endothelium-1-3. On lymphocytes, it mediates binding to high endothelial venules of lymph nodes. As a selectin-4-6 it functions as a calcium-dependent lectin-7,8 recognizing carbohydrate-bearing ligands on endothelial cells-9-11. Two lymph node ligands for L-selectin have been identified as sulphated glycoproteins of M-r apprx 50K and apprx 90K, called Sgp50 and **Sgp90** (ref. 10). The recently cloned Sgp50(ref.12), now designated GlyCAM-1, is a high endothelial venule-associated, mucin-like glycoprotein containing predominantly O-linked carbohydrate chains. Sialylation of GlyCAM-1 is necessary for its ligand activity-9,10,13 and a role for fucosylation is suspected-13. We have used chlorate as a metabolic inhibitor of sulphation, and report here that GlyCAM-1 has an additional requirement for sulphate.



6/7/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08992785 BIOSIS NO.: 199497001155  
L-selectin and its biological ligands.  
AUTHOR: Rosen Steven D  
AUTHOR ADDRESS: Dep. Anat. and Program Immunol., Univ. Calif., San  
Francisco, CA 94143-0452\*\*USA  
JOURNAL: Histochemistry 100 (3):p185-191 1993  
ISSN: 0301-5564  
DOCUMENT TYPE: Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: This review considers the leukocyte adhesive receptor known as L-selectin. This protein, belonging to the selectin family of cell-cell adhesion receptors, mediates adhesion by virtue of a C-type lectin domain at its amino terminus. The protein was discovered as a lymphocyte homing receptor involved in the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes. Its widespread distribution on all leukocyte populations underlies a more general role in a variety of leukocyte-endothelial interactions. In the HEV interaction, cognate HEV ligands for L-selectin have been identified as two sulfated, sialylated, and fucosylated glycoproteins, known as GlyCAM-1 and **Sgp90**. These ligands have mucin-like domains which confer important properties for their proposed adhesive function. The carbohydrate features of these ligands, essential for their interaction with L-selectin, are reviewed. The existence of extra-lymphoid ligands for L-selectin is also discussed.

6/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08992825 BIOSIS NO.: 199497001195  
Binding of L-selectin to the vascular sialomucin CD34.  
AUTHOR: Baumheuter Susanne; Singer Mark S; Henzel William; Hemmerich Stefan  
; Renz Mark; Rosen Steven D; Lasky Laurence A(a)  
AUTHOR ADDRESS: (a)Dep. Immunol., Genentech Inc., South San Francisco, CA  
94080\*\*USA  
JOURNAL: Science (Washington D C) 262 (5132):p436-438 1993  
ISSN: 0036-8075  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: The adhesive interactions between leukocyte L-selectin and the endothelium are involved in the migration of lymphocytes through peripheral lymph nodes and of neutrophils to sites of inflammation. A recombinant L-selectin stains high endothelial venules (HEVs) in lymph nodes and recognizes sulfated carbohydrates found on two endothelial glycoproteins, Sgp50 and **Sgp90**. Amino acid sequencing of purified **Sgp90** revealed a protein core identical to that of CD34, a sialomucin expressed on hematopoietic stem cells and endothelium. A polyclonal antiserum to recombinant murine CD34 stains peripheral lymph node endothelium and recognizes **Sgp90** that is functionally bound by L-selectin. Thus, an HEV glycoform of CD34 can function as a ligand for L-selectin.

09590839 BIOSIS NO.: 199598045757

Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selection and MECA 79, an adhesion-blocking monoclonal antibody.

AUTHOR: Hemmerich Stefan; Butcher Eugene C; Rosen Steven D(a)

AUTHOR ADDRESS: (a)Dep. Anat., Univ. Calif., San Francisco, CA 94143-0452\*\*  
USA

JOURNAL: Journal of Experimental Medicine 180 (6):p2219-2226 1994

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: L-selectin is a lectin-like receptor that mediates the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes during the process of lymphocyte recirculation. Two sulfated, mucin-like glycoproteins known as Sgp50/GlyCAM-1 and **Sgp90**/CD34 have previously been identified as HEV-associated ligands for L-selectin. These proteins were originally detected with an L-selectin/Ig chimera called LEC-IgG. GlyCAM-1 and CD34 are also recognized by an antiperipheral node addressin (PNAd) mAb called MECA 79, which blocks L-selectin-dependent adhesion and selectively stains lymph node HEV. The present study compares the requirements for the binding of MECA 79 and LEC-IgG to HEV-ligands. Whereas desialylation of GlyCAM-1 and CD34 drastically reduced binding to LEC-IgG, this treatment enhanced the binding of GlyCAM-1 to MECA 79. In contrast, the binding of both MECA 79 and LEC-IgG to GlyCAM-1 and CD34 was greatly decreased when the sulfation of these ligands was reduced with chlorate, a metabolic inhibitor of sulfation. Because MECA 79 stains HEV-like vessels at various sites of inflammation, recognition by L-selectin of ligands outside of secondary lymphoid organs may depend on sulfation. In addition to their reactivity with GlyCAM-1 and CD34, both MECA 79 and LEC-IgG recognize an independent molecule of approx 200 kD in a sulfate-dependent manner. Thus, this molecule, which we designate Sgp200, is an additional ligand for

Lat logoff: 15jan00 14:37:56  
Logon file001 15jan00 15:30:46  
□dialog

File 1:ERIC 1966-1999/Oct  
(c) format only 1999 The Dialog Corporation  
\*File 1: File has been reloaded. See HELP NEWS 1.  
Limits of /ED and /EJ currently not working.

Set	Items	Description
---	-----	-----

? b 410

>>>'IALOG' not recognized as set or accession number  
? set hi ;set hi

15jan00 15:30:52 User208760 Session D1417.1		
	\$0.35	0.099 DialUnits File1
\$0.35	Estimated cost File1	
\$0.05	TYMNET	
\$0.40	Estimated cost this search	
\$0.40	Estimated total session cost	0.099 DialUnits

File 410:Chronolog(R) 1981-1999 Nov/Dec  
(c) 1999 The Dialog Corporation plc

Set	Items	Description
---	-----	-----

?  
HILIGHT set on as ''  
HILIGHT set on as ''  
? begin 652,653,654

15jan00 15:31:06 User208760 Session D1417.2		
	\$0.00	0.049 DialUnits File410
\$0.00	Estimated cost File410	
\$0.01	TYMNET	
\$0.01	Estimated cost this search	
\$0.41	Estimated total session cost	0.148 DialUnits

SYSTEM:OS - DIALOG OneSearch  
File 652:US Patents Fulltext 1971-1979  
(c) format only 2000 The Dialog Corp.  
\*File 652: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.  
File 653:US Pat.Fulltext 1980-1989  
(c) format only 2000 Knight-Ridder Info  
\*File 653: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.  
File 654:US Pat.Full. 1990-2000/Jan 11  
(c) format only 2000 The Dialog Corp.  
\*File 654: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.

Set	Items	Description
---	-----	-----

? s (cd34 or sqp90)(40n)(inhibit? or suppress? or antagon? or prevent? or  
decreas? or diminish?)(40n)(inflamm? or adhesi? or autoimmun? or immun?)

>>>File 654 processing for IMMUN? stopped at IMMUNOGLOBULIN  
Processing

```
      492  CD34
      7    SGP90
290327  INHIBIT?
143735  SUPPRESS?
24973   ANTAGON?
1278332 PREVENT?
670962  DECREAS?
100333  DIMINISH?
36013   INFLAMM?
325863  ADHESI?
6715    AUTOIMMUN?
66120   IMMUN?
S1      53  (CD34 OR SGP90) (40N) (INHIBIT? OR SUPPRESS? OR ANTAGON? OR
           PREVENT? OR DECREAS? OR DIMINISH?) (40N) (INFLAMM? OR
           ADHESI? OR AUTOIMMUN? OR IMMUN?)
```

? t s1/3/all

1/3/1 (Item 1 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03061648

Utility

THERAPEUTIC USES OF THE HYPERVARIABLE REGION OF MONOCLONAL ANTIBODY M195  
AND CONSTRUCTS THEREOF

PATENT NO.: 6,007,814  
ISSUED: December 28, 1999 (19991228)  
INVENTOR(s): Scheinberg, David A., New York, NY (New York), US (United  
States of America)  
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company  
or Corporation), New York, NY (New York), US (United States of  
America)  
[Assignee Code(s): 1305]  
APPL. NO.: 7-861,967  
FILED: June 15, 1992 (19920615)

This application is a 371 of PCT-U.S.90-07436 filed Dec. 14, 1990 which  
is a continuation-in-part of U.S. Ser. No. 07-450,918, filed Dec. 14, 1989,  
now abandoned, the contents of which are hereby incorporated by reference  
into the present application.  
FULL TEXT: 4021 lines

1/3/2 (Item 2 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03058293

Utility

IN-VITRO T-LYMPHOPOIESIS SYSTEM

PATENT NO.: 6,004,812  
ISSUED: December 21, 1999 (19991221)  
INVENTOR(s): Scadden, David T., Weston, MA (Massachusetts), US (United  
States of America)  
Freedman, Andrew, Wales, GB (United Kingdom)  
ASSIGNEE(s): Beth Israel Medical Center, Inc , (A U.S. Company or  
Corporation), Boston, MA (Massachusetts), US (United States of  
America)  
APPL. NO.: 9-132,206  
FILED: August 11, 1998 (19980811)

This application is a divisional application of Ser. No. 08-475,679 filed on Jun. 7, 1995, Pending, which in turn is a continuation-in-part application of Ser. No. 08-348,659 filed on Dec. 1, 1994, pending. The contents of all of the aforementioned applications are hereby incorporated by reference.

#### GOVERNMENT SUPPORT

The work described herein was supported, in part, by a grant from the National Institutes of Health (HL 44851). The United States government may have certain rights in the invention.

FULL TEXT: 638 lines

1/3/3 (Item 3 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03058288

Utility  
IN VITRO GENERATION OF HUMAN DENDRITIC CELLS

PATENT NO.: 6,004,807  
ISSUED: December 21, 1999 (19991221)  
INVENTOR(s): Banchereau, Jacques, Ecully, FR (France)  
Caux, Christophe, Lyons, FR (France)  
ASSIGNEE(s): Schering Corporation, (A U.S. Company or Corporation),  
Kenilworth, NJ (New Jersey), US (United States of America)  
[Assignee Code(s): 74480]  
APPL. NO.: 8-637,880  
FILED: April 25, 1996 (19960425)  
PRIORITY: 92400879, EP (European Patent Office), March 30, 1992  
(19920330)

This is a division of U.S. application Ser. No. 331,531, filed Sep. 26, 1994 now abandoned.

FULL TEXT: 543 lines

1/3/4 (Item 4 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03037799

Utility  
METHOD OF IDENTIFYING BIOLOGICAL RESPONSE MODIFIERS INVOLVED IN DENDRITIC  
AND/OR LYMPHOID PROGENITOR CELL PROLIFERATION AND/OR DIFFERENTIATION

PATENT NO.: 5,985,660  
ISSUED: November 16, 1999 (19991116)  
INVENTOR(s): Galy, Anne H. M., Palo Alto, CA (California), US (United  
States of America)  
ASSIGNEE(s): SyStemix, Inc, (A U.S. Company or Corporation), Palo Alto, CA  
(California), US (United States of America)  
[Assignee Code(s): 26755]  
APPL. NO.: 8-482,650  
FILED: June 07, 1995 (19950607)

#### RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 08-464,678 filed on Jun. 6, 1995, now abandoned which is the U.S. national phase of PCT Application Ser. No. PCT-US95-03038 filed on Mar. 9, 1995,

which is a continuation-in-part of U.S. application Ser. No. 08-260,185  
filed on Jun. 15, 1994, now abandoned.

FULL TEXT: 1846 lines

1/3/5 (Item 5 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03037795

Utility  
SUPPRESSOR AND PROGENITOR CELLS

PATENT NO.: 5,985,656  
ISSUED: November 16, 1999 (19991116)  
INVENTOR(s): Strober, Samuel S., Portola Valley, CA (California), US  
(United States of America)  
ASSIGNEE(s): The Board of Trustees of the Leland Stanford Junior University  
, (A U.S. Company or Corporation), Stanford, CA (California),  
US (United States of America)  
[Assignee Code(s): 49136]  
APPL. NO.: 7-971,723  
FILED: November 04, 1992 (19921104)

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation-in-part of U.S. patent application Ser. No.  
07-931,210, filed Aug. 17, 1992, now abandoned, which is a  
continuation-in-part of U.S. patent application Ser. No. 07-789,169, filed  
Nov. 5, 1991, now abandoned, which is a continuation-of-part of U.S. patent  
application Ser. No. 06-873,583, filed Jun. 12, 1986, now abandoned.

FULL TEXT: 1855 lines

1/3/6 (Item 6 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03032734

Utility  
METHODS FOR ENHANCING ANGIOGENESIS WITH ENDOTHELIAL PROGENITOR CELLS

PATENT NO.: 5,980,887  
ISSUED: November 09, 1999 (19991109)  
INVENTOR(s): Isner, Jeffrey M., Weston, MA (Massachusetts), US (United  
States of America)  
Asahara, Takayuki, Arlington, MA (Massachusetts), US (United  
States of America)  
ASSIGNEE(s): St Elizabeth's Medical Center of Boston, (A U.S. Company or  
Corporation), Boston, MA (Massachusetts), US (United States of  
America)  
APPL. NO.: 8-744,882  
FILED: November 08, 1996 (19961108)  
FULL TEXT: 1006 lines

1/3/7 (Item 7 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03023957

Utility  
METHOD OF PURIFYING A POPULATION OF CELLS ENRICHED FOR DENDRITIC AND/OR  
LYMPHOID PROGENITORS AND POPULATIONS OF CELLS OBTAINED THEREBY

PATENT NO.: 5,972,627  
ISSUED: October 26, 1999 (19991026)  
INVENTOR(s): Galy, Anne H. M., Palo Alto, CA (California), US (United States of America)  
ASSIGNEE(s): SyStemix, Inc , (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)  
[Assignee Code(s): 26755]  
APPL. NO.: 8-476,403  
FILED: June 07, 1995 (19950607)

#### RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 08-464,678 filed on Jun. 6, 1995 now abandoned, which is the U.S. national phase of PCT Application Ser. No. PCT-US95-03038 filed on Mar. 9, 1995, which is a continuation-in-part of U.S. application Ser. No. 08-260,185 filed on Jun. 15, 1994 now abandoned.

FULL TEXT: 1867 lines

1/3/8 (Item 8 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03019809

Utility

POSITIVE AND POSITIVE/NEGATIVE CELL SELECTION MEDIATED BY PEPTIDE RELEASE

PATENT NO.: 5,968,753  
ISSUED: October 19, 1999 (19991019)  
INVENTOR(s): Tseng-Law, Janet, Whitter, CA (California), US (United States of America)  
Kobori, Joan A., Pasadena, CA (California), US (United States of America)  
Al-Abdaly, Fahad A., Torrance, CA (California), US (United States of America)  
Guillermo, Roy, Carson, CA (California), US (United States of America)  
Helgerson, Sam L., Pasadena, CA (California), US (United States of America)  
Deans, Robert J., Claremont, CA (California), US (United States of America)  
ASSIGNEE(s): Nexell Therapeutics, Inc , (A U.S. Company or Corporation), Irvine, CA (California), US (United States of America)  
[Assignee Code(s): 47914]  
APPL. NO.: 8-482,228  
FILED: June 07, 1995 (19950607)

This application is a continuation-in-part of U.S. Ser. No. 08-259,427, filed Jun. 14, 1994, now abandoned.

FULL TEXT: 5513 lines

1/3/9 (Item 9 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03012985

Utility

PORCINE CD34

PATENT NO.: 5,962,644  
ISSUED: October 05, 1999 (19991005)



INVENTOR(s): Hawley, Robert J., Newton, MA (Massachusetts), US (United States of America)  
Monroy, Rodney L., Rockport, MA (Massachusetts), US (United States of America)  
ASSIGNEE(s): BioTransplant, Inc , (A U.S. Company or Corporation), Charlestown, MA (Massachusetts), US (United States of America)  
[Assignee Code(s): 40599]  
APPL. NO.: 8-475,634  
FILED: June 07, 1995 (19950607)  
FULL TEXT: 1140 lines

1/3/10 (Item 10 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02987929

Utility  
METHODS AND COMPOSITIONS FOR INHIBITING HIV INFECTION OF CELLS BY CLEAVING HIV CO-RECEPTOR RNA

PATENT NO.: 5,939,538  
ISSUED: August 17, 1999 (19990817)  
INVENTOR(s): Leavitt, Markley C., La Jolla, CA (California), US (United States of America)  
Tritz, Richard, San Diego, CA (California), US (United States of America)  
Feng, Yu, San Diego, CA (California), US (United States of America)  
Barber, Jack, San Diego, CA (California), US (United States of America)  
Yu, Mang, San Diego, CA (California), US (United States of America)  
ASSIGNEE(s): Immusol Incorporated, (A U.S. Company or Corporation), San Diego, CA (California), US (United States of America)  
[Assignee Code(s): 45249]  
APPL. NO.: 8-770,235  
FILED: December 19, 1996 (19961219)

This application claims priority to provisional application Ser. No. 60-027,875, filed Oct. 25, 1996, now abandoned.

FULL TEXT: 1992 lines

1/3/11 (Item 11 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02980116

Utility  
MICROFABRICATED MAGNETIC PARTICLES FOR APPLICATIONS TO AFFINITY BINDING

PATENT NO.: 5,932,097  
ISSUED: August 03, 1999 (19990803)  
INVENTOR(s): Wilson, Robert John, Cupertino, CA (California), US (United States of America)  
ASSIGNEE(s): International Business Machines Corporation, (A U.S. Company or Corporation), Armonk, NY (New York), US (United States of America)  
[Assignee Code(s): 42640]  
APPL. NO.: 9-153,985  
FILED: September 16, 1998 (19980916)

RELATED APPLICATION

This application is a continuation of application Ser. No. 08-982,019 entitled MICROFABRICATED MAGNETIC PARTICLES FOR APPLICATIONS TO AFFINITY BINDING, filed Dec. 1, 1997, still pending.  
FULL TEXT: 1117 lines

1/3/12 (Item 12 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02972981

Utility  
TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR

PATENT NO.: 5,925,349  
ISSUED: July 20, 1999 (19990720)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-916,766  
FILED: August 19, 1997 (19970819)

#### CROSS-REFERENCES

"This application is a divisional of U.S. patent application Ser. No. 08-496,857, filed Jun. 30, 1995, now U.S. Pat. No. 5,695,752, which application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned", which is a continuation-in-part of our earlier filed applications Ser. No. 07-943,817 filed Sep. 11, 1992, now abandoned, and Ser. No. 08-155,947 filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference in their entirety, and to which applications we claim priority under 35 USC selection 120.

#### GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1523 lines

1/3/13 (Item 13 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02952564

Utility  
METHOD OF RECONSTITUTING HEMATOPOIETIC CELLS USING MONOCLONAL ANTIBODIES TO THE STEM CELL FACTOR RECEPTOR

PATENT NO.: 5,906,938  
ISSUED: May 25, 1999 (19990525)  
INVENTOR(s): Broudy, Virginia C., Seattle, WA (Washington), US (United States of America)  
Lin, Nancy, Seattle, WA (Washington), US (United States of America)  
ASSIGNEE(s): Board of Regents of the University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United

States of America)  
[Assignee Code(s): 2937]  
APPL. NO.: 8-449,139  
FILED: May 24, 1995 (19950524)

This is a continuation of U.S. Ser. No. 08-011,078 filed Jan. 29, 1993, U.S. Pat. No. 5,489,516, which is a continuation of U.S. Ser. No. 07-681,245, filed Apr. 5, 1991, now abandoned.

FULL TEXT: 1012 lines

1/3/14 (Item 14 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02925424

Utility

ISOLATION OF NOVEL HIV-2 PROVIRUSES

[ Rev gene hybridizes to second exon; activating deletion; high basal activity; vaccines; packaging cells, transduction vectors, gene therapy; diagnosing]

PATENT NO.: 5,883,081  
ISSUED: March 16, 1999 (19990316)  
INVENTOR(s): Kraus, Gunter, La Jolla, CA (California), US (United States of America)  
Wong-Staal, Flossie, San Diego, CA (California), US (United States of America)  
Talbot, Randy, Princeton, NJ (New Jersey), US (United States of America)  
Poeschla, Eric M., San Diego, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-659,251  
FILED: June 07, 1996 (19960607)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. provisional application U.S. Ser. No. 60-001,441 (Kraus et al.) filed Jul. 26, 1995.

FULL TEXT: 4303 lines

1/3/15 (Item 15 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02901435

Utility

ADENO-ASSOCIATED VIRAL (AAV) LIPOSOMES AND METHODS RELATED THERETO

[ genetic manipulation which comprises a liposome comprised of lipid material, and adeno-associated viral (AAV) material for genomes]

PATENT NO.: 5,861,314  
ISSUED: January 19, 1999 (19990119)  
INVENTOR(s): Philip, Ramila, Redwood City, CA (California), US (United States of America)  
Lebkowski, Jane, Portola Valley, CA (California), US (United States of America)  
ASSIGNEE(s): Rhone-Poulenc Rorer Pharmaceuticals Inc , (A U.S. Company or Corporation), Collegeville, PA (Pennsylvania), US (United

States of America)  
[Assignee Code(s): 24918]  
APPL. NO.: 8-471,603  
FILED: June 06, 1995 (19950606)

This is a division of application Ser. No. 08-120,605 filed Sep. 13, 1993, now abandoned.

FULL TEXT: 953 lines

1/3/16 (Item 16 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02901293

Utility  
ADENO-ASSOCIATED VIRAL (AAV) LIPOSOMES AND METHODS RELATED THERETO  
[Forming a genetic sequence into a T-cell using liposomes]

PATENT NO.: 5,861,171  
ISSUED: January 19, 1999 (19990119)  
INVENTOR(s): Philip, Ramila, Redwood City, CA (California), US (United States of America)  
Lebkowski, Jane, Portola Valley, CA (California), US (United States of America)  
ASSIGNEE(s): Rhone-Poulenc Rorer Pharmaceuticals Inc , (A U.S. Company or Corporation), Collegeville, PA (Pennsylvania), US (United States of America)  
[Assignee Code(s): 24918]  
APPL. NO.: 8-458,342  
FILED: June 02, 1995 (19950602)

This is a division of application Ser. No. 08-120,605 filed Sep. 13, 1993, now abandoned.

FULL TEXT: 944 lines

1/3/17 (Item 17 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02898576

Utility  
FUNCTIONAL HUMAN HEMATOPOIETIC CELLS  
[Purification; transplanting]

PATENT NO.: 5,858,782  
ISSUED: January 12, 1999 (19990112)  
INVENTOR(s): Long, Michael W., Northville, MI (Michigan), US (United States of America)  
Pipia, George G., Ann Arbor, MI (Michigan), US (United States of America)  
ASSIGNEE(s): Regents of the University of Michigan, (A U.S. Company or Corporation), Ann Arbor, MI (Michigan), US (United States of America)  
[Assignee Code(s): 55176]  
APPL. NO.: 8-557,991  
FILED: November 13, 1995 (19951113)  
FULL TEXT: 413 lines

1/3/18 (Item 18 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02895904

Utility  
SERRATE FRAGMENTS AND DERIVATIVES  
[Dna sequences]

PATENT NO.: 5,856,441  
ISSUED: January 05, 1999 (19990105)  
INVENTOR(s): Artavanis-Tsakonas, Spyridon, Hamden, CT (Connecticut), US  
(United States of America)  
Fehon, Richard Grant, Hamden, CT (Connecticut), US (United States of America)  
Rebay, Ilaria, New Haven, CT (Connecticut), US (United States of America)  
ASSIGNEE(s): Yale University, (A U.S. Company or Corporation), New Haven, CT (Connecticut), US (United States of America)  
[Assignee Code(s): 1311]  
APPL. NO.: 8-346,128  
FILED: November 28, 1994 (19941128)

This application is a continuation of application Ser. No. 07-879,038, filed Apr. 30, 1992, now abandoned, which is a continuation-in-part of application Ser. No. 07-791,923 filed Nov. 14, 1991, abandoned, which is a continuation-in-part of application Ser. No. 07-695,189, filed May 3, 1991, abandoned, each of which is incorporated by reference herein in its entirety.

This invention was made in part with government support under Grant numbers GM 29093 and NS 26084 awarded by the Department of Health and Human Services. The government has certain rights in the invention.

FULL TEXT: 4966 lines

1/3/19 (Item 19 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02890560

Utility  
METHOD FOR IN VITRO PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR  
USE TO PRODUCE IMMUNOGENS

PATENT NO.: 5,851,756  
ISSUED: December 22, 1998 (19981222)  
INVENTOR(s): Steinman, Ralph M., Westport, CT (Connecticut), US (United States of America)  
Inaba, Kayo, Kyoto, JP (Japan)  
Schuler, Gerold, Innsbruck, AT (Austria)  
ASSIGNEE(s): The Rockefeller University, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)  
[Assignee Code(s): 3137]  
APPL. NO.: 8-458,230  
FILED: June 02, 1995 (19950602)

This application is a continuation of U.S. patent application Ser. No. 08-040,677 filed Mar. 31, 1993, abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 07-981,357 filed Nov. 25, 1992, abandoned, which in turn is a continuation-in-part of U.S. patent application Ser. No. 07-861,612 filed Apr. 1, 1992, abandoned.

This invention was made with United States Government support under NIH grant AI13013 awarded by the National Institutes of Health. The United States Government has certain rights in this invention. The making of this invention was also supported by the Austrian Government through grants NB

4370 (Austrian National Bank) and P 8549M (Austrian Science Foundation).

FULL TEXT: 2777 lines

1/3/20 (Item 20 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02884723

Utility

INFUSION OF NEUTROPHIL PRECURSORS FOR TREATMENT OF NEUTROPENIA

PATENT NO.: 5,846,529  
ISSUED: December 08, 1998 (19981208)  
INVENTOR(s): Smith, Stephen L., Arlington Heights, IL (Illinois), US  
(United States of America)  
Qiao, Xiaoying, Waukegan, IL (Illinois), US (United States of America)  
Maciukas, Susan M., El Cerrito, CA (California), US (United States of America)  
Loudovaris, Maureen F., Grayslake, IL (Illinois), US (United States of America)  
Bender, James G., Lindenhurst, IL (Illinois), US (United States of America)  
Van Epps, Dennis E., Cary, IL (Illinois), US (United States of America)  
ASSIGNEE(s): Nexell Therapeutics, Inc , (A U.S. Company or Corporation),  
Irvine, CA (California), US (United States of America)  
[Assignee Code(s): 47914]  
APPL. NO.: 8-376,945  
FILED: January 20, 1995 (19950120)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 08-295,378, filed Aug. 23, 1994, which in turn is a continuation-in-part of U.S. Ser. No. 08-110,277, filed Aug. 23, 1993, the contents of both of which are hereby incorporated by reference into the present disclosure.

FULL TEXT: 2136 lines

1/3/21 (Item 21 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02881330

Utility

PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS

PATENT NO.: 5,843,438  
ISSUED: December 01, 1998 (19981201)  
INVENTOR(s): Papayannopoulou, Thalia, Seattle, WA (Washington), US (United States of America)  
ASSIGNEE(s): Board of Regents University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)  
[Assignee Code(s): 2937]  
APPL. NO.: 8-436,339  
FILED: July 13, 1995 (19950713)  
PCT: PCT-US93-11060 (WO 93US11060)  
Section 371 Date: July 13, 1995 (19950713)  
Section 102(e) Date: July 13, 1995 (19950713)  
Filing Date: November 15, 1993 (19931115)  
Publication Number: WO94-11027 (WO 9411027)

Publication Date: May 26, 1995 (19950526)

This application is a national stage application under U.S.C. 371 of PCT-US93-11060, filed Nov. 15, 1993, which is a continuation-in-part of Ser. No. 07-977,702, filed Nov. 13, 1992, now abandoned.

FULL TEXT: 1240 lines

1/3/22 (Item 22 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02871392

Utility

ADENO-ASSOCIATED VIRAL (AAV) LIPOSOMES AND METHODS RELATED THERETO  
[Introducing a genetic sequence into a host cell]

PATENT NO.: 5,834,441  
ISSUED: November 10, 1998 (19981110)  
INVENTOR(s): Philip, Ramila, Redwood City, CA (California), US (United States of America)  
Lebkowski, Jane, Portola Valley, CA (California), US (United States of America)  
ASSIGNEE(s): Rhone-Poulenc Rorer Pharmaceuticals Inc , (A U.S. Company or Corporation), Collegeville, PA (Pennsylvania), US (United States of America)  
[Assignee Code(s): 24918]  
APPL. NO.: 8-305,221  
FILED: September 12, 1994 (19940912)

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. patent application Ser. No.: 08-120,605, entitled "Adeno-Associated Viral (AAV) Liposomes and Methods Related Thereto" which was filed 13 Sep. 1993, now abandoned.

FULL TEXT: 1904 lines

1/3/23 (Item 23 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02867371

Utility

METHOD OF DETECTING HEMATOPOIETIC PROGENITOR CELLS  
[ System of monitoring peripheral blood cells in simple, quickand low-cost manner]

PATENT NO.: 5,830,701  
ISSUED: November 03, 1998 (19981103)  
INVENTOR(s): Houwen, Berend, Redlands, CA (California), US (United States of America)  
Tsujino, Yukio, Hyogo-ken, JP (Japan)  
Morikawa, Takashi, Hyogo-ken, JP (Japan)  
Ikeuchi, Yoshiro, Hyogo-ken, JP (Japan)  
Hamaguchi, Yukio, Hyogo-ken, JP (Japan)  
ASSIGNEE(s): Tao Medical Electronics Co Ltd , (A Non-U.S. Company or Corporation), JP (Japan)  
[Assignee Code(s): 768]  
EXTRA INFO: Assignment transaction [Reassigned], recorded March 25, 1999 (19990325)  
APPL. NO.: 8-829,239  
FILED: March 28, 1997 (19970328)  
FULL TEXT: 532 lines

1/3/24 (Item 24 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02867354

Utility  
PREPARATION OF IMMORTALIZED CELLS  
[Growth suppressor gene]

PATENT NO.: 5,830,682  
ISSUED: November 03, 1998 (19981103)  
INVENTOR(s): Moore, Emma E., Seattle, WA (Washington), US (United States of America)  
ASSIGNEE(s): ZymoGenetics, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)  
[Assignee Code(s): 17415]  
APPL. NO.: 8-770,895  
FILED: December 13, 1996 (19961213)

This application is a continuation-in-part of Ser. No. PCT-US95-11484, filed 11 Sep. 1995, and a continuation-in-part of Ser. No. 08-479,882 filed Jun. 7, 1995, and a continuation-in-part of Ser. No. 08-303,983 filed Sep. 9, 1994. All of the above applications are incorporated by reference in their entirety for all purposes.  
FULL TEXT: 1550 lines

1/3/25 (Item 25 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02867321

Utility  
HYBRIDIZATION AND AMPLIFICATION OF NUCLEIC ACIDS ENCODING MPL LIGAND

PATENT NO.: 5,830,647  
ISSUED: November 03, 1998 (19981103)  
INVENTOR(s): Eaton, Dan L., San Rafael, CA (California), US (United States of America)  
de Sauvage, Frederic J., Foster City, CA (California), US (United States of America)  
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)  
[Assignee Code(s): 7579]  
APPL. NO.: 8-429,764  
FILED: April 26, 1995 (19950426)

This application is a divisional of co-pending U.S. application Ser. No. 08-348,658 filed 2 Dec. 1994, which application is a continuation of U.S. application Ser. No. 08-185,607 filed 21 Jan. 1994 now abandoned, which application is a continuation-in-part of U.S. application Ser. No. 08-176,553 filed 3 Jan. 1994 now abandoned, which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC selection 120.

FULL TEXT: 3143 lines

1/3/26 (Item 26 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02864065

Utility  
METHODS OF ISOLATING AND DETECTING BONE MARROW STROMAL CELLS WITH



VCAM-1-SPECIFIC ANTIBODIES

[ Genetic engineering involving recombinant DNA technology; therapeutic methods for modulating the immune response including treating inflammation in a patient; vascular cell adhesion molecules]

PATENT NO.: 5,827,670

ISSUED: October 27, 1998 (19981027)

INVENTOR(s): Masinovsky, Boris, Bellevue, WA (Washington), US (United States of America)  
Gallatin, William Michael, Mercer Island, WA (Washington), US (United States of America)  
Simmons, Paul J., Seattle, WA (Washington), US (United States of America)

ASSIGNEE(s): Fred Hutchinson Cancer Research Center, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)

[Assignee Code(s): 14990]

APPL. NO.: 8-480,840

FILED: June 07, 1995 (19950607)

This is a Divisional of U.S. application Ser. No. 08-448,649, filed May 24, 1995, which is a Continuation of U.S. application Ser. No. 08-051,455, filed Apr. 21, 1993, now abandoned, which is a Divisional of U.S. application Ser. No. 07-562,008 filed Aug. 2, 1990, now U.S. Pat. No. 5,206,345.

This invention was made with government support under Public Health Service grants CA40272, P30 CA15704, and RR00166. The government has certain rights in this invention.

FULL TEXT: 1360 lines

1/3/27 (Item 27 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02860425

Utility

PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS

[Treating AIDS, cancer, gene therapy]

PATENT NO.: 5,824,304

ISSUED: October 20, 1998 (19981020)

INVENTOR(s): Papayannopoulou, Thalia, 702 35th Ave., Seattle, WA (Washington), US (United States of America), 98122  
[Assignee Code(s): 68000]

APPL. NO.: 8-463,298

FILED: June 05, 1995 (19950605)

This is a division of copending application Ser. No. 08-436,339, filed Nov. 15, 1993 which is a continuation-in-part of abandoned application Ser. No. 07-977,702, filed Nov. 13, 1992.

FULL TEXT: 1234 lines

1/3/28 (Item 28 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02846585

Utility

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF:  
IMMUNODEPRESSANTS

PATENT NO.: 5,811,399  
ISSUED: September 22, 1998 (19980922)  
INVENTOR(s): Khavinson, Vladimir Kh., St. Petersburg, RU (Russian Federation)  
Morozov, Vyacheslav G., St. Petersburg, RU (Russian Federation)  
ASSIGNEE(s): Cytran, Inc , (A U.S. Company or Corporation), Kirkland, WA (Washington), US (United States of America)  
[Assignee Code(s): 45946]  
APPL. NO.: 8-450,904  
FILED: May 26, 1995 (19950526)

This application is a continuation-in-part of Ser. No. 08-337,341 filed Nov. 10, 1994 now U.S. Pat. No. 5,538,951, and a continuation-in-part of Ser. No. 08-278,463 filed Jul. 21, 1994 (abandoned), said Ser. No. 08-337,341 filed Nov. 10, 1994 which is a continuation-in-part of Ser. No. 08-257,495 filed Jun. 7, 1994 (abandoned), which is a continuation of Ser. No. 07-783,518 filed Oct. 28, 1991 (abandoned), which is a continuation-in-part of Ser. No. 07-678,129 filed Apr. 1, 1991 (abandoned), which is a continuation-in-part of Ser. No. 07-415,283 filed Aug. 30, 1989 (abandoned), which is a 371 of PCT-SU88-00255 filed Dec. 14, 1988. All the above patent applications are hereby incorporated by reference.

FULL TEXT: 10093 lines

1/3/29 (Item 29 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02846462

Utility  
HIV-SPECIFIC RIBOZYMES  
[Genetic engineering]

PATENT NO.: 5,811,275  
ISSUED: September 22, 1998 (19980922)  
INVENTOR(s): Wong-Staal, Flossie, San Diego, CA (California), US (United States of America)  
Yu, Mang, San Diego, CA (California), US (United States of America)  
Yamada, Osamu, San Diego, CA (California), US (United States of America)  
Ojwang, Joshua O., Spring, TX (Texas), US (United States of America)  
Leavitt, Mark, La Jolla, CA (California), US (United States of America)  
Ho, Anthony, San Diego, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-465,483  
FILED: June 05, 1995 (19950605)  
DISCLAIMER: September 23, 2017 (20170923)

This application is a continuation of U.S. Ser. No. 08-245,742, filed May 17, 1994, which is a continuation-in-part of U.S. Ser. No. 08-062,465, filed May 17, 1993, now abandoned, the contents of which are incorporated herein by reference.

The Government has rights in this invention pursuant to Contract No. DAMD 17-90-C-0094 awarded by the United States Army.

FULL TEXT: 2421 lines

1/3/30 (Item 30 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02846279

Utility

PHARMACEUTICAL PREPARATION BASED ON FETAL SUSPENSION AND METHODS OF  
TREATING ACQUIRED IMMUNE DEFICIENCY SYNDROME (HIV INJECTION)  
[ Improving the patient immune system by administering at least one dosage  
of human embryo cells]

PATENT NO.: 5,811,089  
ISSUED: September 22, 1998 (19980922)  
INVENTOR(s): Smikodub, Alexandr Ivanovich, Kiev, UA (Ukraine)  
Markov, Igor Semenovich, Kiev, UA (Ukraine)  
Pilipchak, Elena Makarovna, Kiev, UA (Ukraine)  
ASSIGNEE(s): Centr Embrionainikh Tkaney "'Emcell'", (A Non-U.S. Company or  
Corporation), Kiev, UAX  
[Assignee Code(s): 46969]  
EXTRA INFO: Assignment transaction [Reassigned], recorded November 4,  
1998 (19981104)  
APPL. NO.: 8-505,236  
FILED: August 09, 1995 (19950809)  
PRIORITY: 94061620, UAX, December 14, 1993 (19931214)  
PCT: PCT-UA94-00026 (WO 94UA26)  
Section 371 Date: August 09, 1995 (19950809)  
Section 102(e) Date: August 09, 1995 (19950809)  
Filing Date: October 17, 1994 (19941017)  
Publication Number: WO95-16455 (WO 9516455)  
Publication Date: June 22, 1995 (19950622)  
FULL TEXT: 2172 lines

1/3/31 (Item 31 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02842782

Utility

METHOD FOR TREATMENT OF PURULENT INFLAMMATORY DISEASES  
[Administering glutamic acid, tryptophan dipeptide]

PATENT NO.: 5,807,830  
ISSUED: September 15, 1998 (19980915)  
INVENTOR(s): Morozov, Vyacheslav G., St. Petersburg, RU (Russian  
Federation)  
Khavinson, Vladimir Kh., St. Petersburg, RU (Russian  
Federation)  
ASSIGNEE(s): Cytoven J V , (A U.S. Company or Corporation), Kirkland, WA  
(Washington), US (United States of America)  
[Assignee Code(s): 39334]  
APPL. NO.: 8-452,061  
FILED: May 26, 1995 (19950526)  
PRIORITY: 4352833, SU (USSR), December 30, 1987 (19871230)

This application is a continuation-in-part of application Ser. No.  
337,341 filed Nov. 10, 1994, now U.S. Pat. No. 5,538,951 and a  
continuation-in-part of Ser. No. 08-278,463, filed Jul. 21, 1994  
(abandoned), which is a continuation-in-part of application Ser. No.  
08-257,495, filed Jun. 7, 1994 (abandoned), which is a continuation of  
application Ser. No. 07-783,518, filed Oct. 28, 1991 (abandoned), which is  
a continuation-in-part of Ser. No. 07-678,129, filed Apr. 1, 1991

(abandoned), which is a continuation-in-part of application Ser. No. 07-415,283, filed Aug. 30, 1989 (abandoned), which is a United States national stage application of PCT-SU88-00255, filed Dec. 14, 1988, which claims the benefit of the filing date of Soviet application SU 4,352,833, filed Dec. 30, 1987. This application also claims the benefit of the filing date of U.S. patent application Ser. No. 08-337,341, filed Nov. 10, 1994, now issued as U.S. Pat. No. 5,538,951, whose specification is identical to Ser. No. 07-415,283. All of the above applications are hereby incorporated by reference.

FULL TEXT: 10218 lines

1/3/32 (Item 32 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02842698

Utility  
USE OF INTERFERON .GAMMA. FOR THE INHIBITION OF PROLIFERATION AND  
DIFFERENTIATION OF PRIMITIVE HEMATOPOIETIC PROGENITOR CELLS  
[Incubation; separation of bone marrow and tumor cells]

PATENT NO.: 5,807,744  
ISSUED: September 15, 1998 (19980915)  
INVENTOR(s): Berneman, Zwi, Antwerp, BE (Belgium)  
Van Bockstaele, Dirk, Edegem, BE (Belgium)  
Snoeck, Hans-Willem, Antwerp, BE (Belgium)  
ASSIGNEE(s): Boehringer Mannheim GmbH, (A Non-U.S. Company or Corporation),  
Mannheim, DE (Germany)  
[Assignee Code(s): 10203]  
APPL. NO.: 8-514,897  
FILED: August 14, 1995 (19950814)  
PRIORITY: 94112688.0, EP (European Patent Office), August 13, 1994  
(19940813)  
FULL TEXT: 923 lines

1/3/33 (Item 33 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02829469

Utility  
MONO-PEGYLATED PROTEINS THAT STIMULATE MEGAKARYOCYTE GROWTH AND  
DIFFERENTIATION  
[Polypeptides]

PATENT NO.: 5,795,569  
ISSUED: August 18, 1998 (19980818)  
INVENTOR(s): Bartley, Timothy D., Thousand Oaks, CA (California), US  
(United States of America)  
Bogenberger, Jakob M., Camarillo, CA (California), US (United  
States of America)  
Bosselman, Robert A., Thousand Oaks, CA (California), US  
(United States of America)  
Hunt, Pamela, Thousand Oaks, CA (California), US (United  
States of America)  
Kinstler, Olaf B., Oxnard, CA (California), US (United States  
of America)  
Samal, Babru B., Moorpark, CA (California), US (United States  
of America)  
ASSIGNEE(s): Amgen Inc , (A U.S. Company or Corporation), Thousand Oaks, CA  
(California), US (United States of America)  
[Assignee Code(s): 12117]  
APPL. NO.: 8-321,488

FILED: October 12, 1994 (19941012)

This application is a continuation-in-part of application Ser. No. 08-252,628, filed May 31, 1994, which is a continuation-in part of application Ser. No. 08-221,768, filed Mar. 31, 1994, abandoned.

FULL TEXT: 3567 lines

1/3/34 (Item 34 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02822742

Utility  
ALPHAVIRUS STRUCTURAL PROTEIN EXPRESSION CASSETTES  
[Genetic engineering]

PATENT NO.: 5,789,245  
ISSUED: August 04, 1998 (19980804)  
INVENTOR(s): Dubensky, Jr. Thomas W., Rancho Sante Fe, CA (California), US  
(United States of America)  
Polo, John M., San Diego, CA (California), US (United States of America)  
Ibanez, Carlos E., San Diego, CA (California), US (United States of America)  
Chang, Stephen M. W., San Diego, CA (California), US (United States of America)  
Jolly, Douglas J., Leucadia, CA (California), US (United States of America)  
Driver, David A., San Diego, CA (California), US (United States of America)  
ASSIGNEE(s): Chiron Corporation, (A U.S. Company or Corporation),  
Emeryville, CA (California), US (United States of America)  
[Assignee Code(s): 11661]  
APPL. NO.: 8-741,881  
FILED: October 30, 1996 (19961030)

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No. 08-404,796, filed Mar. 15, 1995; which application is a continuation-in-part of U.S. patent application Ser. No. 08-376,184, filed Jan. 20, 1995, now abandoned; which application is a continuation-in-part of U.S. patent application Ser. No. 08-348,472, filed Nov. 30, 1994, now abandoned; which application is a continuation-in-part of U.S. patent application Ser. No. 08-198,450, filed Feb. 18, 1994, now abandoned; which application is a continuation-in-part of U.S. patent application Ser. No. 08-122,791, filed Sep. 15, 1993, now abandoned.

FULL TEXT: 10072 lines

1/3/35 (Item 35 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02822696

Utility  
HUMAN NOTCH AND DELTA, BINDING DOMAINS IN TOPORYTHMIC PROTEINS, AND METHODS BASED THEREON  
[DNA, nucleotide sequences, proteins and genes]

PATENT NO.: 5,789,195  
ISSUED: August 04, 1998 (19980804)  
INVENTOR(s): Artavanis-Tsakonas, Spyridon, Hamden, CT (Connecticut), US

(United States of America)  
Muskavitch, Marc Alan Telander, Bloomington, IN (Indiana), US  
(United States of America)  
Fehon, Richard Grant, Hamden, CT (Connecticut), US (United  
States of America)  
Rebay, Ilaria, New Haven, CT (Connecticut), US (United States  
of America)  
Blaumueller, Christine Marie, New Haven, CT (Connecticut), US  
(United States of America)  
Shepard, Scott Brockwell, Bloomington, IN (Indiana), US  
(United States of America)  
ASSIGNEE(s): Yale University, (A U.S. Company or Corporation), New Haven,  
CT (Connecticut), US (United States of America)  
[Assignee Code(s): 1311]  
APPL. NO.: 8-465,500  
FILED: June 05, 1995 (19950605)

This is a division of application Ser. No. 08-264,534, filed Jun. 23, 1994, now U.S. Pat. No. 5,648,464 which is a continuation of application Ser. No. 07-695,189 filed May 3, 1991, now abandoned.

This invention was made in part with government support under Grant numbers GM 29093 and NS 26084 awarded by the Department of Health and Human Services. The government has certain rights in the invention.

FULL TEXT: 4622 lines

1/3/36 (Item 36 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02803471

Utility  
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF: SYSTEMIC  
TOXICITY  
[ Administering glutamic acid-tryptophan dipeptide to stimulate binding  
function of T-lymphocytes]

PATENT NO.: 5,770,576  
ISSUED: June 23, 1998 (19980623)  
INVENTOR(s): Morozov, Vyacheslav G., St. Petersburg, RU (Russian  
Federation)  
Khavinson, Vladimir Kh., St. Petersburg, RU (Russian  
Federation)  
ASSIGNEE(s): Cytran, Inc , (A U.S. Company or Corporation), Kirkland, WA  
(Washington), US (United States of America)  
[Assignee Code(s): 45946]  
EXTRA INFO: Assignment transaction [Reassigned], recorded September 1,  
1998 (19980901)  
APPL. NO.: 8-452,077  
FILED: May 26, 1995 (19950526)

This application is a continuation-in-part of application Ser. No 08-278,463 filed Jul. 21, 1994 (abandoned) which is a continuation-in-part of application Ser. No. 08-257,495 filed Jun. 7, 1994 (abandoned) which is a continuation of Ser. No 07-783,518 filed Oct. 28, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-678,129 filed Apr. 1, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-415,283 filed Aug. 30, 1989 (abandoned). Application Ser. No. 07-415,283 is a national stage application of PCT-SU88,00255 filed Dec. 14, 1988 which claims a priority date from SU Patent 4,352,833 filed Dec. 30, 1987. Application Ser. No. 08-337,341 filed Nov. 10, 1994 is a divisional of Ser. No. 07-415,283 and issued as U.S. Pat. No. 5,538,951. All the above patent applications are hereby incorporated by reference.

FULL TEXT: 10093 lines

1/3/37 (Item 37 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02799739

Utility  
T CELL DIFFERENTIATION OF CD34+ STEM CELLS IN CULTURED THYMIC EPITHELIAL  
FRAGMENTS  
[Immunocompetence]

PATENT NO.: 5,766,944  
ISSUED: June 16, 1998 (19980616)  
INVENTOR(s): Ruiz, Margaret Eileen, 4202 E. West Highway, Chevy Chase, MD  
(Maryland), US (United States of America), 20815  
[Assignee Code(s): 68000]  
APPL. NO.: 8-775,509  
FILED: December 31, 1996 (19961231)  
FULL TEXT: 1382 lines

1/3/38 (Item 38 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02799389

Utility  
SYSTEMIC GENE TREATMENT OF CONNECTIVE TISSUE DISEASES WITH IRAP-1  
[ Infecting bone marrow cells with recombinant retroviral expression vector  
that contains a polynucleotide sequence coding a biologically active  
interleukin receptor antagonist protein, injecting into host;  
antiinflammatory agents]

PATENT NO.: 5,766,585  
ISSUED: June 16, 1998 (19980616)  
INVENTOR(s): Evans, Christopher H., Pittsburgh, PA (Pennsylvania), US  
(United States of America)  
Robbins, Paul D., Pittsburgh, PA (Pennsylvania), US (United  
States of America)  
ASSIGNEE(s): University of Pittsburgh of the Commonwealth System of Higher  
Education, (A U.S. Company or Corporation), Pittsburgh, PA  
(Pennsylvania), US (United States of America)  
[Assignee Code(s): 66208]  
APPL. NO.: 8-697,180  
FILED: August 20, 1996 (19960820)  
This application is a continuation of application Ser. No. 08-167,642,  
filed Dec. 14, 1993, now abandoned.

FULL TEXT: 1740 lines

1/3/39 (Item 39 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02799385

Utility  
METHOD FOR TREATING MAMMALS WITH MONOPEGYLATED PROTEINS THAT STIMULATES  
MEGAKARYOCYTE GROWTH AND DIFFERENTIATION  
[ Increasing platelet number with POLYPEPTIDE molecules attached to  
polyethylene glycol]

PATENT NO.: 5,766,581  
ISSUED: June 16, 1998 (19980616)

INVENTOR(s): Bartley, Timothy D., Thousand Oaks, CA (California), US  
(United States of America)  
Bogenberger, Jakob M., Camarillo, CA (California), US (United  
States of America)  
Bosselman, Robert A., Thousand Oaks, CA (California), US  
(United States of America)  
Hunt, Pamela, Thousand Oaks, CA (California), US (United  
States of America)  
Kinstler, Olaf B., Thousand Oaks, CA (California), US (United  
States of America)  
Samal, Babru B., Moorpark, CA (California), US (United States  
of America)  
ASSIGNEE(s): Amgen Inc , (A U.S. Company or Corporation), Thousand Oaks, CA  
(California), US (United States of America)  
[Assignee Code(s): 12117]  
APPL. NO.: 8-413,803  
FILED: March 30, 1995 (19950330)

This application is a continuation of application Ser. No. 08-347,780,  
filed Nov. 30, 1994, which is a continuation-in-part of application Ser.  
No. 08-321,488, filed Oct. 12, 1994, which is a continuation-in-part of  
application Ser. No. 08-252,628, filed May 31, 1994, which is a  
continuation-in part of application Ser. No. 08,221,768, filed Mar. 31,  
1994, abandoned, each of which is hereby incorporated by reference.

FULL TEXT: 4077 lines

1/3/40 (Item 40 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02778869

Utility

ADENOVIRAL-MEDIATED GENE TRANSFER TO SYNOVIAL CELLS IN VIVO

PATENT NO.: 5,747,072  
ISSUED: May 05, 1998 (19980505)  
INVENTOR(s): Davidson, Beverly L., Howell, MI (Michigan), US (United States  
of America)  
Roessler, Blake J., Ann Arbor, MI (Michigan), US (United  
States of America)  
ASSIGNEE(s): University of Michigan, (A U.S. Company or Corporation), Ann  
Arbor, MI (Michigan), US (United States of America)  
[Assignee Code(s): 55176]  
APPL. NO.: 8-422,655  
FILED: April 14, 1995 (19950414)

This application is a continuation of application Ser. No. 08-100,646,  
filed Jul. 30, 1993, now abandoned.

FULL TEXT: 826 lines

1/3/41 (Item 41 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02773146

Utility

ANTI-HIV RIBOZYMES

[Endo-ribonuclease nucleic acid encoding a ribozyme which cleaves an RNA]

PATENT NO.: 5,741,706  
ISSUED: April 21, 1998 (19980421)  
INVENTOR(s): Leavitt, Markley C., San Diego, CA (California), US (United



States of America)  
Tritz, Richard, San Diego, CA (California), US (United States of America)  
Duarte, Elizabeth, San Diego, CA (California), US (United States of America)  
Barber, Jack, San Diego, CA (California), US (United States of America)  
Yu, Mang, San Diego, CA (California), US (United States of America)  
ASSIGNEE(s): Immusol, Incorporated, (A U.S. Company or Corporation), San Diego, CA (California), US (United States of America)  
[Assignee Code(s): 45249]  
APPL. NO.: 8-719,593  
FILED: September 25, 1996 (19960925)  
FULL TEXT: 1743 lines

1/3/42 (Item 42 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02758931

Utility  
METHODS FOR NORMALIZING NUMBERS OF LYMPHOCYTES  
[Administering glutamic acid-tryptophan dipeptide; immunomodulation]

PATENT NO.: 5,728,680  
ISSUED: March 17, 1998 (19980317)  
INVENTOR(s): Morozov, Vyacheslav G., St. Petersburg, RU (Russian Federation)  
Khavinson, Vladimir Kh., St. Petersburg, RU (Russian Federation)  
ASSIGNEE(s): Cytoven J V , (A U.S. Company or Corporation), Kirkland, WA (Washington), US (United States of America)  
[Assignee Code(s): 39334]  
EXTRA INFO: Assignment transaction [Reassigned], recorded September 1, 1998 (19980901)  
APPL. NO.: 8-452,411  
FILED: May 26, 1995 (19950526)  
PRIORITY: 4352833, SU (USSR), December 30, 1987 (19871230)

This application is a continuation-in-part of application Ser. No. 08-337,341 filed Nov. 10, 1994 (now U.S. Pat. No. 5,538,951), and is a continuation-in-part of Ser. No. 08-278,463 filed Jul. 21, 1994 (abandoned). Ser. No. 08-278,463 is a continuation-in-part of application Ser. No. 08-257,495 filed Jun. 7, 1994 (abandoned) which is a continuation of Ser. No. 07-783,518 filed Oct. 28, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-678,129 filed Apr. 1, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-415,283 filed Aug. 30, 1989 (abandoned). Application Ser. No. 07-415,283 is a national stage application of PCT-SU88-00255 filed Dec. 14, 1988 which claims a priority date from SU Patent 4,352,833 filed Dec. 30, 1987. All the above patent applications are hereby incorporated by reference.

FULL TEXT: 9006 lines

1/3/43 (Item 43 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721614

Utility  
PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS  
[Treating cancer]

PATENT NO.: 5,695,755  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Papayannopoulou, Thalia, 3336 Cascadia Ave. South, Seattle, WA  
(Washington), US (United States of America), 98144  
[Assignee Code(s): 68000]  
APPL. NO.: 8-463,128  
FILED: June 05, 1995 (19950605)

This is a division of copending application Ser. No. 08-436,339, filed Nov. 15, 1993 which is a continuation-in-part of abandoned application Ser. No. 07-977,702, filed Nov. 13, 1992.

FULL TEXT: 1223 lines

1/3/44 (Item 44 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721611

Utility  
TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES  
AND/OR SULFATION INHIBITOR

PATENT NO.: 5,695,752  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-496,857  
FILED: June 30, 1995 (19950630)

#### CROSS-REFERENCES

This application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned, which is a continuation-in-part of earlier filed U.S. application Ser. No. 07-943,817, filed Sep. 11, 1992, now abandoned, and earlier filed U.S. application Ser. No. 08-155,947, filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference and to which applications we claim priority under 35 U.S.C. selection 120.

#### GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1641 lines

1/3/45 (Item 45 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02719055

Utility  
HUMAN BREAST CARCINOMA CELL LINE CAPABLE OF PRODUCTION OF A SPONTANEOUSLY METASTASIZING TUMOR IN ANIMALS FOR USE IN ANTICANCER DRUG TESTING  
[Human aneuploid breast carcinoma cell line stable in vitro]

PATENT NO.: 5,693,533  
ISSUED: December 02, 1997 (19971202)  
INVENTOR(s): Raney, Shula, Fort Lauderdale, FL (Florida), US (United States of America)  
Emma, Dennis, Miramar, FL (Florida), US (United States of America)  
Hurst, Josephine, Fort Lauderdale, FL (Florida), US (United States of America)  
ASSIGNEE(s): The Goodwin Institute for Cancer Research, (A U.S. Company or Corporation), Plantation, FL (Florida), US (United States of America)  
[Assignee Code(s): 43903]  
APPL. NO.: 8-350,938  
FILED: December 07, 1994 (19941207)  
FULL TEXT: 304 lines

1/3/46 (Item 46 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02708351

Utility  
PREPARATION OF IMMORTALIZED CELLS  
[ Culture of bone marrow tissue for growth suppressor gene deficient growth medium, isolation and analyzing]

PATENT NO.: 5,683,906  
ISSUED: November 04, 1997 (19971104)  
INVENTOR(s): Moore, Emma E., Seattle, WA (Washington), US (United States of America)  
ASSIGNEE(s): ZymoGenetics, Inc , (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)  
[Assignee Code(s): 17415]  
APPL. NO.: 8-303,983  
FILED: September 09, 1994 (19940909)  
FULL TEXT: 791 lines

1/3/47 (Item 47 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02693161

Utility  
HIV-SPECIFIC RIBOZYMES  
[Insertion retrovirus into nucleic acid]

PATENT NO.: 5,670,361  
ISSUED: September 23, 1997 (19970923)  
INVENTOR(s): Wong-Staal, Flossie, San Diego, CA (California), US (United States of America)  
Yu, Mang, San Diego, CA (California), US (United States of America)  
Yamada, Osamu, Kobe, JP (Japan)  
Ojwang, Joshua O., Spring, TX (Texas), US (United States of America)  
Leavitt, Markley C., La Jolla, CA (California), US (United States of America)  
Ho, Anthony, San Diego, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-245,742

FILED: May 17, 1994 (19940517)

This application is a continuation-in-part of U.S. Ser. No. 08-062,465, filed May 17, 1993 now abandoned, the contents of which are incorporated herein by reference.

The Government has rights in this invention pursuant to Contract No. DAMD 17-90-C-0094 awarded by the United States Army.

FULL TEXT: 2448 lines

1/3/48 (Item 48 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02685011

Utility

SEPARATION APPARATUS AND METHOD

[Centrifuging device with closure, constriction and channels for cell separation]

PATENT NO.: 5,663,051  
ISSUED: September 02, 1997 (19970902)  
INVENTOR(s): Vlasselaer, Peter Van, Sunnyvale, CA (California), US (United States of America)  
ASSIGNEE(s): Activated Cell Therapy, Inc , (A U.S. Company or Corporation), Mountain View, CA (California), US (United States of America)  
[Assignee Code(s): 37594]  
EXTRA INFO: Assignment transaction [Reassigned], recorded June 30, 1998 (19980630)  
APPL. NO.: 8-570,397  
FILED: December 11, 1995 (19951211)

This is a continuation-in-part of U.S. patent application Ser. No. 08-299,469 now U.S. Pat. No. 5,474,687, and a continuation-in-part of application Ser. No. 08-299,465, U.S. Ser. No. 08-299,467 and U.S. Ser. No. 08-299,468, all filed Aug. 31, 1994.

FULL TEXT: 2867 lines

1/3/49 (Item 49 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02668481

Utility

HUMAN NOTCH AND DELTA BINDING DOMAINS IN TOPORYTHMIC PROTEINS, AND METHODS BASED THEREON

PATENT NO.: 5,648,464  
ISSUED: July 15, 1997 (19970715)  
INVENTOR(s): Artavanis-Tsakonas, Spyridon, Hamden, CT (Connecticut), US (United States of America)  
Fehon, Richard Grant, New Haven, CT (Connecticut), US (United States of America)  
Rebay, Ilaria, New Haven, CT (Connecticut), US (United States of America)  
Blaumueller, Christine Marie, New Haven, CT (Connecticut), US (United States of America)  
ASSIGNEE(s): Yale University, (A U.S. Company or Corporation), New Haven, CT (Connecticut), US (United States of America)  
[Assignee Code(s): 1311]  
APPL. NO.: 8-264,534

FILED: June 23, 1994 (19940623)

This is a continuation of application Ser. No. 07-695,189 filed May 3, 1991, now abandoned.

Pursuant to the provisions of 35 U.S.C. selection 202(c), it is hereby acknowledged that the Government has certain rights in this invention, which was made in part with funds from the National Institutes of Health.

This invention was made in part with government support under Grant numbers GM 29093 and NS 26084 awarded by the Department of Health and Human Services. The government has certain fights in the invention.

FULL TEXT: 4654 lines

1/3/50 (Item 50 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02640726

Utility  
T LYMPHOCYTE PRECURSOR  
[Specific antigens]

PATENT NO.: 5,622,853  
ISSUED: April 22, 1997 (19970422)  
INVENTOR(s): Terstappen, Leon W. M. M., Palo Alto, CA (California), US  
(United States of America)  
Picker, Louis J., Dallas, TX (Texas), US (United States of America)  
ASSIGNEE(s): Becton Dickinson and Company, (A U.S. Company or Corporation),  
Franklin Lakes, NJ (New Jersey), US (United States of America)  
[Assignee Code(s): 8488]  
APPL. NO.: 7-669,142  
FILED: March 14, 1991 (19910314)

This application is a continuation-in-part of an earlier filed application Ser. No. 517,101, filed May 1,1990, now abandoned.

FULL TEXT: 867 lines

1/3/51 (Item 51 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02636446

Utility  
ANTISENSE OLIGONUCLEOTIDES SPECIFIC FOR STK-1 AND METHOD FOR INHIBITING  
EXPRESSION OF THE STK-1 PROTEIN  
[Antitumor agents]

PATENT NO.: 5,618,709  
ISSUED: April 08, 1997 (19970408)  
INVENTOR(s): Gewirtz, Alan M., Philadelphia, PA (Pennsylvania), US (United States of America)  
Small, Donald, Baltimore, MD (Maryland), US (United States of America)  
Civin, Curt I., Baltimore, MD (Maryland), US (United States of America)  
ASSIGNEE(s): The Johns Hopkins University, (A U.S. Company or Corporation),  
Baltimore, MD (Maryland), US (United States of America)  
University of Pennsylvania, (A U.S. Company or Corporation),  
Philadelphia, PA (Pennsylvania), US (United States of America)  
[Assignee Code(s): 39884; 64664]

APPL. NO.: 8-183,211  
FILED: January 14, 1994 (19940114)

REFERENCE TO GOVERNMENT GRANT

The invention described herein was supported in part by the National Institutes of Health grants CA36896, CA54384 and CA51083. The United States Government has certain rights in the invention.

FULL TEXT: 1642 lines

1/3/52 (Item 52 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02598707

Utility  
T LYMPHOCYTE PRECURSOR  
[ Mixing the sample cell with at least three monoclonal antibodies capable reacting with antigen]

PATENT NO.: 5,583,033  
ISSUED: December 10, 1996 (19961210)  
INVENTOR(s): Terstappen, Leon W. M. M., Palo Alto, CA (California), US  
(United States of America)  
Picker, Louis J., Dallas, TX (Texas), US (United States of America)  
ASSIGNEE(s): Becton Dickinson and Company, (A U.S. Company or Corporation),  
Franklin Lakes, NJ (New Jersey), US (United States of America)  
[Assignee Code(s): 8488]  
APPL. NO.: 8-139,293  
FILED: October 19, 1993 (19931019)

This is a continuation of application Ser. No. 669,142, filed Mar. 14, 1991, which is a continuation-in-part of an earlier filed application Ser. No. 517,101, filed May 1, 1990, now abandoned.

FULL TEXT: 896 lines

1/3/53 (Item 53 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02479449

Utility  
METHODS FOR ENRICHING CD34.SUP.+ HUMAN HEMATOPOIETIC PROGENITOR CELLS  
[ Layering cell mixture into centrifuge tube having annular member with opening and containing density gradient solution, centrifuging to pelletize cells having higher densities, collecting cells enriched in desired cells from upper portion]

PATENT NO.: 5,474,687  
ISSUED: December 12, 1995 (19951212)  
INVENTOR(s): Van Vlasselaer, Peter, Sunnyvale, CA (California), US (United States of America)  
ASSIGNEE(s): Activated Cell Therapy, Inc, (A U.S. Company or Corporation),  
Mountain View, CA (California), US (United States of America)  
[Assignee Code(s): 37594]  
EXTRA INFO: Assignment transaction [Reassigned], recorded June 30, 1998 (19980630)  
APPL. NO.: 8-299,469  
FILED: August 31, 1994 (19940831)  
FULL TEXT: 1159 lines  
?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES  
? t sl/3/1,5,12,13,26,27,28,35,42,43,44,49,50,52

1/3/1 (Item 1 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03061648

Utility

THERAPEUTIC USES OF THE HYPERVARIABLE REGION OF MONOCLONAL ANTIBODY M195  
AND CONSTRUCTS THEREOF

PATENT NO.: 6,007,814  
ISSUED: December 28, 1999 (19991228)  
INVENTOR(s): Scheinberg, David A., New York, NY (New York), US (United  
States of America)  
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company  
or Corporation), New York, NY (New York), US (United States of  
America)  
[Assignee Code(s): 1305]  
APPL. NO.: 7-861,967  
FILED: June 15, 1992 (19920615)

This application is a 371 of PCT-U.S.90-07436 filed Dec. 14, 1990 which  
is a continuation-in-part of U.S. Ser. No. 07-450,918, filed Dec. 14, 1989,  
now abandoned, the contents of which are hereby incorporated by reference  
into the present application.  
FULL TEXT: 4021 lines

1/3/5 (Item 5 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03037795

Utility

SUPPRESSOR AND PROGENITOR CELLS

PATENT NO.: 5,985,656  
ISSUED: November 16, 1999 (19991116)  
INVENTOR(s): Strober, Samuel S., Portola Valley, CA (California), US  
(United States of America)  
ASSIGNEE(s): The Board of Trustees of the Leland Stanford Junior University  
, (A U.S. Company or Corporation), Stanford, CA (California),  
US (United States of America)  
[Assignee Code(s): 49136]  
APPL. NO.: 7-971,723  
FILED: November 04, 1992 (19921104)

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation-in-part of U.S. patent application Ser. No.  
07-931,210, filed Aug. 17, 1992, now abandoned, which is a  
continuation-in-part of U.S. patent application Ser. No. 07-789,169, filed  
Nov. 5, 1991, now abandoned, which is a continuation-of-part of U.S. patent  
application Ser. No. 06-873,583, filed Jun. 12, 1986, now abandoned.

FULL TEXT: 1855 lines

1/3/12 (Item 12 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02972981

Utility  
TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES  
AND/OR SULFATION INHIBITOR

PATENT NO.: 5,925,349  
ISSUED: July 20, 1999 (19990720)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-916,766  
FILED: August 19, 1997 (19970819)

CROSS-REFERENCES

"This application is a divisional of U.S. patent application Ser. No. 08-496,857, filed Jun. 30, 1995, now U.S. Pat. No. 5,695,752, which application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned", which is a continuation-in-part of our earlier filed applications Ser. No. 07-943,817 filed Sep. 11, 1992, now abandoned, and Ser. No. 08-155,947 filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference in their entirety, and to which applications we claim priority under 35 USC selection 120.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1523 lines

1/3/13 (Item 13 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02952564

Utility  
METHOD OF RECONSTITUTING HEMATOPOIETIC CELLS USING MONOCLONAL ANTIBODIES TO  
THE STEM CELL FACTOR RECEPTOR

PATENT NO.: 5,906,938  
ISSUED: May 25, 1999 (19990525)  
INVENTOR(s): Broudy, Virginia C., Seattle, WA (Washington), US (United States of America)  
Lin, Nancy, Seattle, WA (Washington), US (United States of America)  
ASSIGNEE(s): Board of Regents of the University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)  
[Assignee Code(s): 2937]  
APPL. NO.: 8-449,139  
FILED: May 24, 1995 (19950524)

This is a continuation of U.S. Ser. No. 08-011,078 filed Jan. 29, 1993, U.S. Pat. No. 5,489,516, which is a continuation of U.S. Ser. No. 07-681,245, filed Apr. 5, 1991, now abandoned.

FULL TEXT: 1012 lines



1/3/26 (Item 26 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02864065

Utility

METHODS OF ISOLATING AND DETECTING BONE MARROW STROMAL CELLS WITH VCAM-1-SPECIFIC ANTIBODIES

[ Genetic engineering involving recombinant DNA technology; therapeutic methods for modulating the immune response including treating inflammation in a patient; vascular cell adhesion molecules]

PATENT NO.: 5,827,670  
ISSUED: October 27, 1998 (19981027)  
INVENTOR(s): Masinovsky, Boris, Bellevue, WA (Washington), US (United States of America)  
Gallatin, William Michael, Mercer Island, WA (Washington), US (United States of America)  
Simmons, Paul J., Seattle, WA (Washington), US (United States of America)  
ASSIGNEE(s): Fred Hutchinson Cancer Research Center, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)  
[Assignee Code(s): 14990]  
APPL. NO.: 8-480,840  
FILED: June 07, 1995 (19950607)

This is a Divisional of U.S. application Ser. No. 08-448,649, filed May 24, 1995, which is a Continuation of U.S. application Ser. No. 08-051,455, filed Apr. 21, 1993, now abandoned, which is a Divisional of U.S. application Ser. No. 07-562,008 filed Aug. 2, 1990, now U.S. Pat. No. 5,206,345.

This invention was made with government support under Public Health Service grants CA40272, P30 CA15704, and RR00166. The government has certain rights in this invention.

FULL TEXT: 1360 lines

1/3/27 (Item 27 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02860425

Utility

PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS

[Treating AIDS, cancer, gene therapy]

PATENT NO.: 5,824,304  
ISSUED: October 20, 1998 (19981020)  
INVENTOR(s): Papayannopoulou, Thalia, 702 35th Ave., Seattle, WA (Washington), US (United States of America), 98122  
[Assignee Code(s): 68000]  
APPL. NO.: 8-463,298  
FILED: June 05, 1995 (19950605)

This is a division of copending application Ser. No. 08-436,339, filed Nov. 15, 1993 which is a continuation-in-part of abandoned application Ser. No. 07-977,702, filed Nov. 13, 1992.

FULL TEXT: 1234 lines

1/3/28 (Item 28 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02846585

Utility

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF:  
IMMUNODEPRESSANTS

PATENT NO.: 5,811,399  
ISSUED: September 22, 1998 (19980922)  
INVENTOR(s): Khavinson, Vladimir Kh., St. Petersburg, RU (Russian Federation)  
Morozov, Vyacheslav G., St. Petersburg, RU (Russian Federation)  
ASSIGNEE(s): Cytran, Inc , (A U.S. Company or Corporation), Kirkland, WA (Washington), US (United States of America)  
[Assignee Code(s): 45946]  
APPL. NO.: 8-450,904  
FILED: May 26, 1995 (19950526)

This application is a continuation-in-part of Ser. No. 08-337,341 filed Nov. 10, 1994 now U.S. Pat. No. 5,538,951, and a continuation-in-part of Ser. No. 08-278,463 filed Jul. 21, 1994 (abandoned), said Ser. No. 08-337,341 filed Nov. 10, 1994 which is a continuation-in-part of Ser. No. 08-257,495 filed Jun. 7, 1994 (abandoned), which is a continuation of Ser. No. 07-783,518 filed Oct. 28, 1991 (abandoned), which is a continuation-in-part of Ser. No. 07-678,129 filed Apr. 1, 1991 (abandoned), which is a continuation-in-part of Ser. No. 07-415.283 filed Aug. 30, 1989 (abandoned), which is a 371 of PCT-SU88-00255 filed Dec. 14, 1988. All the above patent applications are hereby incorporated by reference.

FULL TEXT: 10093 lines

1/3/35 (Item 35 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02822696

Utility

HUMAN NOTCH AND DELTA, BINDING DOMAINS IN TOPORYTHMIC PROTEINS, AND METHODS BASED THEREON

[DNA, nucleotide sequences, proteins and genes]

PATENT NO.: 5,789,195  
ISSUED: August 04, 1998 (19980804)  
INVENTOR(s): Artavanis-Tsakonas, Spyridon, Hamden, CT (Connecticut), US (United States of America)  
Muskavitch, Marc Alan Telander, Bloomington, IN (Indiana), US (United States of America)  
Fehon, Richard Grant, Hamden, CT (Connecticut), US (United States of America)  
Rebay, Ilaria, New Haven, CT (Connecticut), US (United States of America)  
Blaumueller, Christine Marie, New Haven, CT (Connecticut), US (United States of America)  
Shepard, Scott Brockwell, Bloomington, IN (Indiana), US (United States of America)  
ASSIGNEE(s): Yale University, (A U.S. Company or Corporation), New Haven, CT (Connecticut), US (United States of America)  
[Assignee Code(s): 1311]  
APPL. NO.: 8-465,500  
FILED: June 05, 1995 (19950605)

This is a division of application Ser. No. 08-264,534, filed Jun. 23,

1994, now U.S. Pat. No. 5,648,464 which is a continuation of application Ser. No. 07-695,189 filed May 3, 1991, now abandoned.

This invention was made in part with government support under Grant numbers GM 29093 and NS 26084 awarded by the Department of Health and Human Services. The government has certain rights in the invention.

FULL TEXT: 4622 lines

1/3/42 (Item 42 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02758931

Utility

METHODS FOR NORMALIZING NUMBERS OF LYMPHOCYTES

[Administering glutamic acid-tryptophan dipeptide; immunomodulation]

PATENT NO.: 5,728,680  
ISSUED: March 17, 1998 (19980317)  
INVENTOR(s): Morozov, Vyacheslav G., St. Petersburg, RU (Russian Federation)  
Khavinson, Vladimir Kh., St. Petersburg, RU (Russian Federation)  
ASSIGNEE(s): Cytoven J V, (A U.S. Company or Corporation), Kirkland, WA (Washington), US (United States of America)  
[Assignee Code(s): 39334]  
EXTRA INFO: Assignment transaction [Reassigned], recorded September 1, 1998 (19980901)  
APPL. NO.: 8-452,411  
FILED: May 26, 1995 (19950526)  
PRIORITY: 4352833, SU (USSR), December 30, 1987 (19871230)

This application is a continuation-in-part of application Ser. No. 08-337,341 filed Nov. 10, 1994 (now U.S. Pat. No. 5,538,951), and is a continuation-in-part of Ser. No. 08-278,463 filed Jul. 21, 1994 (abandoned). Ser. No. 08-278,463 is a continuation-in-part of application Ser. No. 08-257,495 filed Jun. 7, 1994 (abandoned) which is a continuation of Ser. No. 07-783,518 filed Oct. 28, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-678,129 filed Apr. 1, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-415,283 filed Aug. 30, 1989 (abandoned). Application Ser. No. 07-415,283 is a national stage application of PCT-SU88-00255 filed Dec. 14, 1988 which claims a priority date from SU Patent 4,352,833 filed Dec. 30, 1987. All the above patent applications are hereby incorporated by reference.

FULL TEXT: 9006 lines

1/3/43 (Item 43 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721614

Utility

PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS

[Treating cancer]

PATENT NO.: 5,695,755  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Papayannopoulou, Thalia, 3336 Cascadia Ave. South, Seattle, WA (Washington), US (United States of America), 98144  
[Assignee Code(s): 68000]  
APPL. NO.: 8-463,128

FILED: June 05, 1995 (19950605)

This is a division of copending application Ser. No. 08-436,339, filed Nov. 15, 1993 which is a continuation-in-part of abandoned application Ser. No. 07-977,702, filed Nov. 13, 1992.

FULL TEXT: 1223 lines

1/3/44 (Item 44 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721611

Utility

TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES  
AND/OR SULFATION INHIBITOR

PATENT NO.: 5,695,752  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-496,857  
FILED: June 30, 1995 (19950630)

#### CROSS-REFERENCES

This application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned, which is a continuation-in-part of earlier filed U.S. application Ser. No. 07-943,817, filed Sep. 11, 1992, now abandoned, and earlier filed U.S. application Ser. No. 08-155,947, filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference and to which applications we claim priority under 35 U.S.C. selection 120.

#### GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1641 lines

1/3/49 (Item 49 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02668481

Utility

HUMAN NOTCH AND DELTA BINDING DOMAINS IN TOPORYTHMIC PROTEINS, AND METHODS  
BASED THEREON

PATENT NO.: 5,648,464  
ISSUED: July 15, 1997 (19970715)  
INVENTOR(s): Artavanis-Tsakonas, Spyridon, Hamden, CT (Connecticut), US (United States of America)  
Fehon, Richard Grant, New Haven, CT (Connecticut), US (United States of America)  
Rebay, Ilaria, New Haven, CT (Connecticut), US (United States

of America)  
Blaumueller, Christine Marie, New Haven, CT (Connecticut), US  
(United States of America)  
ASSIGNEE(s): Yale University, (A U.S. Company or Corporation), New Haven,  
CT (Connecticut), US (United States of America)  
[Assignee Code(s): 1311]  
APPL. NO.: 8-264,534  
FILED: June 23, 1994 (19940623)  
This is a continuation of application Ser. No. 07-695,189 filed May 3,  
1991, now abandoned.

Pursuant to the provisions of 35 U.S.C. section 202(c), it is hereby  
acknowledged that the Government has certain rights in this invention,  
which was made in part with funds from the National Institutes of Health.

This invention was made in part with government support under Grant  
numbers GM 29093 and NS 26084 awarded by the Department of Health and Human  
Services. The government has certain fights in the invention.

FULL TEXT: 4654 lines

1/3/50 (Item 50 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02640726

Utility  
T LYMPHOCYTE PRECURSOR  
[Specific antigens]

PATENT NO.: 5,622,853  
ISSUED: April 22, 1997 (19970422)  
INVENTOR(s): Terstappen, Leon W. M. M., Palo Alto, CA (California), US  
(United States of America)  
Picker, Louis J., Dallas, TX (Texas), US (United States of  
America)  
ASSIGNEE(s): Becton Dickinson and Company, (A U.S. Company or Corporation),  
Franklin Lakes, NJ (New Jersey), US (United States of America)  
[Assignee Code(s): 8488]  
APPL. NO.: 7-669,142  
FILED: March 14, 1991 (19910314)

This application is a continuation-in-part of an earlier filed  
application Ser. No. 517,101, filed May 1,1990, now abandoned.

FULL TEXT: 867 lines

1/3/52 (Item 52 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02598707

Utility  
T LYMPHOCYTE PRECURSOR  
[ Mixing the sample cell with at least three monoclonal antibodies capable  
reacting with antigen]

PATENT NO.: 5,583,033  
ISSUED: December 10, 1996 (19961210)  
INVENTOR(s): Terstappen, Leon W. M. M., Palo Alto, CA (California), US  
(United States of America)  
Picker, Louis J., Dallas, TX (Texas), US (United States of  
America)

ASSIGNEE(s): Becton Dickinson and Company, (A U.S. Company or Corporation),  
Franklin Lakes, NJ (New Jersey), US (United States of America)  
[Assignee Code(s): 8488]  
APPL. NO.: 8-139,293  
FILED: October 19, 1993 (19931019)

This is a continuation of application Ser. No. 669,142, filed Mar. 14, 1991, which is a continuation-in-part of an earlier filed application Ser. No. 517,101, filed May 1, 1990, now abandoned.

FULL TEXT: 896 lines  
? t sl/k/1,5,12,13,26,27,28,35,42,43,44,49,50,52

1/K/1 (Item 1 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

1/K/5 (Item 5 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... engraftment has occurred. The chimeric character of the host is also such that subsequently introduced **immunocompetent** cells will not attack host tissue. These chimeras are thus not only specifically receptive to...tissue from the original donor.

In effecting engraftment, cells enriched in the cell surface marker **CD34** are known to be helpful, since this marker appears to characterize "stem" or "progenitor" cells...

... will be dependent on the enrichment of the transplanted cells in cells which bear the **CD34** marker.

The recipient normal adult host must, of course, be **prevented** from succumbing to an acute **immune** response effected by the originally administered bone marrow cells. The DNS and null NS cells are capable of muting the immediate **immune** response and any other antidonor response sufficiently to permit the generation of characteristics of the chimera. Both fresh and cloned DNS and null cells are also capable of **preventing** the in vivo graft versus host **immune** response. The secreted factor is capable of **inhibiting** the immune response of donor against host, and host against donor cells in vitro, and...CD4 sup + and/or CD8 sup + lymphocytes. The efficacy of the cell composition as a **suppressive** reagent can be confirmed by its mixed lymphocyte reaction (MLR) in vitro.

These **suppressive** cells lines and cell preparations are useful in conjunction with bone marrow and organ transplants in **preventing** graft-versus-host disease (GVHD) and in encouraging the engraftment of the transplanted allografts so...to prepare and expand these cell compositions and cell lines, and to their uses in **suppression** of the **immune** response, as well as to pharmaceutical compositions containing them.

In still another aspect, the invention...

... mononuclear white blood cells, and to methods to prepare this population. This population, enriched in **CD34** surface marker, is thus obtainable by retrieving the white blood cell mononuclear subfraction of the appropriate density.

In another aspect, the invention is directed to a soluble **suppressor** factor secreted by natural **suppressor** cells. This factor is useful in various conditions where unwanted **immune** responses occur. Thus, an additional aspect relates to treating these conditions with the soluble factor...

... The composition of this low density fraction is such that the

composition is capable of **suppressing** the mixed lymphocyte reaction, but preferably is not capable of killing the corresponding target cell...

... In order to show these characteristics, this low density fraction must have a ratio of **suppressor** cells, either or both null NS cells or DNS cells, whose **suppressive** activity is not outweighed by the **immunoactivity** of helper and cytotoxic T-cells bearing CD4 and CD8 markers. In addition, this low density fraction may include progenitor cells such as **CD34** sup + cells, or may be supplemented with such ... the NS cells or the protein factor, as above. The initial simultaneous administration may use **immunocompetent** donor tissue, or donor bone marrow or the bone marrow hematopoietic stem cells.

For allogenic transplants, the **suppressor** cells are preferably derived from the donor in the case of bone marrow transplants, and from the recipient in the case of organ transplants. For use in treatment of **autoimmune** disorders, the patient is used as the source of the **suppressor** cells.

The cell populations of the invention which are enriched in **CD34+** stem cells are useful both in allogenic and autologous transplantation protocols. While in autologous transplantation **suppressor** functionality is not required, capability to engraft is extremely important. Thus, the cell populations obtained by the method of the invention which have high populations of **CD34+** cells as compared to unsorted populations are helpful in encouraging the success of the transplant...

1/K/12 (Item 12 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... receptor. Impairing such binding interrupts the biochemical chain of events which, in excess, leads to **inflammation**. By interrelating such facts we deduced that it would be possible to alleviate and/or **prevent inflammation** in two ways. First, we endeavored to find a compound which would **inhibit** sulfation, i.e. **inhibit** the addition of a sulfate moiety onto a natural selectin ligand--thereby **preventing** complete formation of the ligand. We found that chlorates act to **inhibit** biochemical sulfation of GlyCAM-1 and **CD34/Sgp90** and thereby **prevent** their ability to bind to L-selectin.

1/K/13 (Item 13 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...or fragment thereof.

14. The method of claim 12 wherein the antibody or fragment thereof **decreases** the growth rate by at least one tenth.

15. The method of claim 12 wherein the antibody or fragment thereof **decreases** the growth rate by at least one hundredth.

16. The method of claims 8 or...

...wherein step (b) comprises column chromatography, fluorescence-activated cell sorting, magnetic bead separation or direct **immune** adherence.

18. The method of claims 9 or 13 wherein the second antibody is an anti-**CD34** antibody.

1/K/26 (Item 26 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

...protein synthesis," Cell, Immunol. 119:41-52, (1989).

Rabin, E.M. et al., "Interferon- gamma **inhibits** the action of B cell stimulatory factor (BSF)-1 on resting B cells," J. Immunol. 137:1573-1576, (1986).

Zanjani et al., "Human **CD34+** Cells Transplanted in Utero in Sheep Fetuses Treated with Anti-Human VLA sub 4 Remain Homeless and Persist in Circulation," Blood 84:494a (1994).

Rice et al. "Inducible Cell **Adhesion** Molecular 110 (INCAM-110) is an Endothelial Receptor for Lymphocytes. A **CD11/CD18**-independent **Adhesion** Mechanism," J Exp. Med. 171:1369-1374 (1990).

Rice et al., "An inducible endothelial cell surface glycoprotein mediates melanoma **adhesion**", Science, 246:1303-1306 (1989).

Rothlein, R., et al., "A human intercellular **adhesion** molecule (ICAM-1) distinct from LFA-1," J. Immunol. 137:1270-1274, (1986).

Sandmaier et...

1/K/27 (Item 27 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

...Growth Factors; A Review", J. Clin.Pharmacol, 32, pp. 486-501 (1992).

Ryan et al., "**Inhibition** of Human Bone Marrow Lymphoid Progenitor Colonies by Antibodies to VLA Integrins", J.Immunol., 149, 11, pp. 3759-3764 (1992).

Siena et al., "Circulation of **CD34+** Hematopoietic Stem Cells in the Peripheral Blood of High-Dose Cyclophosphamide--Treated Patients: Enhanced by...

...Stimulating Factor", Blood, 74, No. 6, pp. 1905-1914 (1989).

Simmons et al., "Vascular Cell **Adhesion** Molecule--1 Expressed by Bone Marrow Stromal Cells Mediates the Binding of Hematopieotic Progenitor Cells Blood, 81, No. 9, pp. 2283-2289 (1993).

Teixido et al., "Human **CD34+** Progenitor Cell **Adhesion** to Marrow Stroma is Mediated by VLA--4/VCAM and VLA5/Fibronectin", Blood, 78, Suppl ...  
...1200 (1991).

Teixido et al., "Role of beta 1 and beta 2 Integrins in the **Adhesion** of Human **CD34hi** Stem Cells to Bone Marrow Stroma", J. Clin. Invest., 90, pp. 358...

... 1, VLA-5/fibronectin and beta sub 2 -integrin/ICAM-1 are all important for **adhesion** between bone marrow stromal cells and cells expressing high levels of **CD34**. Simmons et al., Blood 80:388-395 (1992), teaches that in an in vitro model, **adhesion** between stromal cells and **CD34** sup + cells was predominantly dependent on the VLA-4/VCAM-1 interaction and was largely **inhibited** by monoclonal antibodies to either VLA-4 or VCAM-1, with fibronectin playing a minor...

...Williams et al., Nature 352:438-441 (1991), using in vivo mouse studies, teaches that **adhesion** of murine hematopoietic stem cells to stromal cell extracellular matrix (ECM) is partly promoted by...



... is likely to be mediated by VLA-4. All of these studies utilized antibodies to **prevent** adherence between stem cells and their microenvironment. However, none have analyzed whether such interactions are ... cells to the patient's circulating blood. This step serves a "mopping up" function to **prevent** residual virus from infecting the progeny of the newly returned stem cells.

In another aspect...

...that mediates blocking of VLA-4 antigens on the surface of hematopoietic stem cells and **CD34** sup + cells. As in the method previously described herein, this agent may be administered alone...

... then collected by leukapheresis. Stem cells are then enriched from the collected peripheral blood by **immunoadsorption** using anti-**CD34** antibodies. Optionally, the enriched stem cells are then expanded ex vivo by culturing them in...

1/K/28 (Item 28 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... an in vitro assay with mononuclear phagocytes or neutrophils from a sample of blood; (viii) **decreasing** an abnormally enlarged spleen or increasing a small spleen to more effectively combat infection (e...

... number of neutrophils in a measured volume of a tissue infiltrate in response to an **inflammatory** agent; and/or (xiii) increasing the percentage of phagocytically active cells in a neutrophil infiltrate...

... methods of the invention find a variety of prophylactic and therapeutic uses in treatment of **immune** pathophysiologic conditions ...invention find use during in vitro maintenance and expansion of bone marrow, peripheral blood leukocytes, **CD34** sup + lymphocytes, and other **immune** cells, such as may occur prior to autologous or allogenic bone marrow transplantation.

In one...

... an R'-Glu-Trp-R" pharmaceutical preparation is administered to an individual with a diagnosed **autoimmune** disease in an amount and for a time sufficient to **decrease** one or more laboratory indicia of the disease state in the patient. Representative examples of...

1/K/35 (Item 35 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

... et al., 1994, "A Human Homologue of the Drosophila Developmental Gene, Notch, Is Expressed in **CD34+** Hematopoietic Precursors", Blood 83: 2057-2062.

Nye et al., 1994, "An Activated Notch **suppresses** neurogenesis and myogenesis but not gliogenesis in mammalian cells", Development 120: 2421-2430.

Snow et al., 1989, "Fascillin III: A Novel Homophilic **Adhesion** Molecule in Drosophila", Cell 59: 313-323.

Zagouras et al., 1995, "Alterations in Notch signalling...

1/K/42 (Item 42 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... number of neutrophils in a measured volume of a tissue infiltrate in response to an **inflammatory** agent; and/or (xiii) increasing the percentage of phagocytically active cells in a neutrophil infiltrate in treatment of **immune** pathophysiologic conditions in man and domestic animals. In certain embodiments the methods of the invention find use during in vitro maintenance and expansion of bone marrow, peripheral blood leukocytes, **CD34** sup + lymphocytes, and other **immune** cells such as may occur prior to autologous or allogenic bone marrow transplantation.

In one...

... an R'-Glu-Trp-R" pharmaceutical preparation is administered to an individual with a diagnosed **autoimmune** disease in an amount and for a time sufficient to **decrease** one or more laboratory indicia of the disease state in the patient. Representative examples of...

1/K/43 (Item 43 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

...Growth Factors: A Review", J. Clin.Pharmacol, 32, pp. 486-501 (1992).

Ryan et al., "**Inhibition** of Human Bone Marrow Lymphoid Progenitor Colonies by Antibodies to VLA Integrins", J.Immunol., 149, 11, pp. 3759-64 (1992).

Siena et al., "Circulation of **CD34**+ Hematopoietic Stem Cells in the Peripheral Blood of High-Dose Cyclophosphamide-Treated Patients: Enhancement by...

...Stimulating Factor", Blood, 74, No. 6, pp. 1905-1914 (1989).

Simmons et al., "Vascular Cell **Adhesion** Molecule-1 Expressed by Bone Marrow Stromal Cells Mediates the Binding of Hematopoietic Progenitor Cells", Blood, 80, 388-395 (1992).

Teixido et al., "Human **CD34**+ Progenitor Cell **Adhesion** to Marrow Stroma is Mediated by ...1200 (1991).

Teixido et al., "Role of beta 1 and beta 2 Integrins in the **Adhesion** of Human **CD34**hi Stem Cells to Bone Marrow Stroma", J. Clin. Invest., 90, pp. 358...

... 1, VLA-5/fibronectin and beta sub 2 -integrin/ICAM-1 are all important for **adhesion** between bone marrow stromal cells and cells expressing high levels of **CD34**. Simmons et al., Blood 80:388-395 (1992), teaches that in an in vitro model, **adhesion** between stromal cells and **CD34** sup + cells was predominantly dependent on the VLA-4/VCAM-1 interaction and was largely **inhibited** by monoclonal antibodies to either VLA-4 or VCAM-1, with fibronectin playing a minor...

...Williams et al., Nature 352:438-441 (1991), using in vivo mouse studies, teaches that **adhesion** of murine hematopoietic stem cells to stromal cell extracellular matrix (ECM) is partly promoted by...

... is likely to be mediated by VLA-4. All of these studies utilized antibodies to **prevent** adherence between stem cells and their microenvironment. However, none have analyzed whether such interactions are ... cells to the patient's circulating blood. This step serves a "mopping up" function to **prevent** residual virus from infecting the progeny of the newly returned stem cells.

In another aspect...

...that mediates blocking of VLA-4 antigens on the surface of hematopoietic

stem cells and **CD34** sup + cells. As in the method previously described herein, this agent may be administered alone...

... then collected by leukapheresis. Stem cells are then enriched from the collected peripheral blood by **immunoabsorption** using anti-**CD34** antibodies. Optionally, the enriched stem cells are then expanded ex vivo by culturing them in...

1/K/44 (Item 44 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... receptor. Impairing such binding interrupts the biochemical chain of events which, in excess, leads to **inflammation**. By interrelating such facts we deduced that it would be possible to alleviate and/or **prevent inflammation** in two ways. First, we endeavored to find a compound which would **inhibit** sulfation, i.e. **inhibit** the addition of a sulfate moiety onto a natural selectin ligand--thereby **preventing** complete formation of the ligand. We found that chlorates act to **inhibit** biochemical sulfation of GlyCAM-1 and **CD34/Sgp90** and thereby **prevent** their ability to bind to L-selectin.

1/K/49 (Item 49 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

... et al., 1994, "A Human Homologue of the Drosophila Developmental Gene, Notch, Is Expressed in **CD34** # Hematopoietic Precursors", Blood 83: 2057-2062.

Nye et al., 1994, "An activated Notch **suppresses** neurogenesis and myogenesis but not gliogenesis in mammalian cells", Development 120: 2421-2430.

Snow et al., 1989, "Fasciclin III: A Novel Homophilic **Adhesion** Molecule in Drosophila", Cell 59: 313-323.

Zagouras et al., 1995, "Alterations in Notch signaling...

1/K/50 (Item 50 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... four described stages. Stage B I was defined by the relatively high expression of both **CD34** and CD10. In stage B II, expression of **CD34 decreased** to very low levels, CD10 expression **decreased** slightly and levels of CD19, HLA-DP and HLA-DR increased significantly. In stages B...

... hematopoietic system in that these cells produce antibodies that form a major component of the **immune** system. T lymphocytes, on the other hand, have a number of functions which form another major component of the **immune** system. T lymphocytes help B lymphocytes make antibodies, recognize and destroy cells infected with viruses...

1/K/52 (Item 52 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... four described stages. Stage B I was defined by the relatively high expression of both **CD34** and CD10. In stage B II, expression of **CD34 decreased** to very low levels, CD10 expression **decreased** slightly and levels of CD19, HLA-DP and HLA-DR increased significantly. In stages B **immune** system. T lymphocytes, on the other

hand, have a number of functions which form another major component of the **immune** system. T lymphocytes help B lymphocytes make antibodies, recognize and destroy cells infected with viruses...

Culture characterization of differentiated high endothelial venule cells from human tonsils.

Baekkevold ES; Jahnsen FL; Johansen FE; Bakke O; Gaudernack G; Brandtzaeg P; Haraldsen G

Laboratory for Immunohistochemistry and Immunopathology (LIIPAT), Institute of Pathology, University of Oslo, The National Hospital, Norway. e.s.bakkevold@labmed.uio.no

Lab Invest (UNITED STATES) Mar 1999, 79 (3) p327-36, ISSN 0023-6837  
Journal Code: KZ4

Languages: ENGLISH

Document type: JOURNAL ARTICLE

High endothelial venules (HEV) are specialized vessels that support abundant lymphocyte emigration from peripheral blood into secondary lymphoid organs. HEV endothelial cells (HEVEC) exhibit particular structural and functional features, including secretion of the HEV-specific extracellular matrix **protein** hevin and an array of uniquely glycosylated counter-receptors for L-selectin expressed on lymphocytes. These ligands are collectively called the peripheral lymph node addressin (PNAd), originally defined by the monoclonal antibody MECA-79. PNAd expression was used to purify HEVEC by positive immunoselection from enzyme-digested human tonsils after negative immunoselection for other cells. Purified HEVEC maintained secretion of hevin and homogenous expression of intercellular **adhesion** molecule (ICAM)-1 (CD54), ICAM-2 (CD102), and CD31, at high levels following 8 days in culture. Expression of functional PNAd was maintained during the first 4 to 5 days of culture but **decreased** gradually and disappeared on day 8, while the expression of **CD34** remained strong. However, the **CD34** glycoform shifted toward the in situ phenotype of flat-walled vessels, suggesting that the observed loss of L-selectin binding determinants and MECA-79 antigen was due to down-regulation of the glycosyl- and sulfo-transferases essential for their expression. Our rapid and reproducible method to establish HEVEC cultures provides a useful mechanistic tool for identification of the factors that induce and maintain the HEV phenotype, as well as a source for isolation of HEV-specific genes.

E No: 1994357259

Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, an adhesion-blocking monoclonal antibody

Hemmerich S.; Butcher E.C.; Rosen S.D.

Department of Anatomy, University of California, San Francisco, CA

94143-0452 United States

Journal of Experimental Medicine ( J. EXP. MED. ) (United States) 1994, 180/6 (2219-2226)

CODEN: JEMEA ISSN: 0022-1007

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

L-selectin is a lectin-like receptor that mediates the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes during the process of lymphocyte recirculation. Two sulfated, mucin-like glycoproteins known as Sgp50/GlyCAM-1 and Sgp90/CD34 have previously been identified as HEV-associated ligands for L-selectin. These **proteins** were originally detected with an L-selectin/Ig chimera called LEC-IgG. GlyCAM-1 and **CD34** are also recognized by an anti-peripheral node addressin (PNAd) mAb called MECA 79, which blocks L-selectin-dependent **adhesion** and selectively stains lymph node HEV. The present study compares the requirements for the binding of MECA 79 and LEC-IgG to HEV-ligands. Whereas desialylation of GlyCAM-1 and **CD34** drastically reduced binding to LEC-IgG, this treatment enhanced the binding of GlyCAM-1 to MECA 79. In contrast, the binding of both MECA 79 and LEC-IgG to GlyCAM-1 and **CD34** was greatly **decreased** when the sulfation of these ligands was reduced with chlorate, a metabolic **inhibitor** of sulfation. Because MECA 79 stains HEV-like vessels at various sites of **inflammation**, recognition by L-selectin of ligands outside of secondary lymphoid organs may depend on sulfation. In addition to their reactivity with GlyCAM-1 and **CD34**, both MECA 79 and LEC-IgG recognize an independent molecule of ~200 kD in a sulfate-dependent manner. Thus, this molecule, which we designate Sgp200, is an additional ligand for

09589849 BIOSIS NO.: 199598044767

Detection of an L-selectin ligand on a hematopoietic progenitor cell line.

AUTHOR: Oxley Susan M; Sackstein Robert(a)

AUTHOR ADDRESS: (a)Div. Bone Marrow Transplantation, Room 3151, H. Lee  
Moffitt Cancer Cent., 12902 Magnolia Dr., Ta\*\*USA

JOURNAL: Blood 84 (10):p3299-3306 1994

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: L-selectin, the peripheral lymph node "homing receptor," is an **adhesion protein** that mediates lymphocyte binding to lymph node high endothelial venules. Ligands for this **protein** have been identified only on endothelial cells, and recent murine studies indicate that **CD34** on endothelial cells is an L-selectin ligand. To investigate whether **CD34** expressed on hematopoietic cells functions as an L-selectin ligand, we used an in vitro binding assay to examine lymphocyte adherence to KGla, a **CD34+** human hematopoietic progenitor cell line. We observed specific L-selectin-mediated adherence of lymphocytes to KGla: the binding was calcium-dependent, was strictly **inhibited** by anti-L-selectin antibodies and by carbohydrate ligands of L-selectin, and was abrogated by induction of L-selectin shedding from the lymphocyte membrane by treatment with phorbol esters. However, blocking studies using anti-CD34 antibodies, and experiments using KGla cells sorted for CD34 expression and COS-7 cells transfected with full-length CD34 cDNA indicate that the ligand on KGla is not CD34; moreover, RPMI 8402, a CD34+ cell line, does not support lymphocyte adherence in the binding assay. Treatment of KGla with the enzymes neuraminidase, chymotrypsin, and bromelain abrogated lymphocyte binding to the cells, indicating that the ligand is a glycoprotein. These experiments show that CD34 on hematopoietic cells is not an L-selectin ligand and provide the first evidence of a ligand for L-selectin present

09590839 BIOSIS NO.: 199598045757

Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selection and MECA 79, an adhesion-blocking monoclonal antibody.

AUTHOR: Hemmerich Stefan; Butcher Eugene C; Rosen Steven D(a)

AUTHOR ADDRESS: (a)Dep. Anat., Univ. Calif., San Francisco, CA 94143-0452\*\*  
USA

JOURNAL: Journal of Experimental Medicine 180 (6):p2219-2226 1994

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: L-selectin is a lectin-like receptor that mediates the attachment of lymphocytes to high endothelial venules (HEV) of lymph nodes during the process of lymphocyte recirculation. Two sulfated, mucin-like glycoproteins known as Sgp50/GlyCAM-1 and Sgp90/**CD34** have previously been identified as HEV-associated ligands for L-selectin. These **proteins** were originally detected with an L-selectin/Ig chimera called LEC-IgG. GlyCAM-1 and **CD34** are also recognized by an antiperipheral node addressin (PNAd) mAb called MECA 79, which blocks L-selectin-dependent **adhesion** and selectively stains lymph node HEV. The present study compares the requirements for the binding of MECA 79 and LEC-IgG to HEV-ligands. Whereas desialylation of GlyCAM-1 and **CD34** drastically reduced binding to LEC-IgG, this treatment enhanced the binding of GlyCAM-1 to MECA 79. In contrast, the binding of both MECA 79 and LEC-IgG to GlyCAM-1 and **CD34** was greatly **decreased** when the sulfation of these ligands was reduced with chlorate, a metabolic **inhibitor** of sulfation. Because MECA 79 stains HEV-like vessels at various sites of **inflammation**, recognition by L-selectin of ligands outside of secondary lymphoid organs may depend on sulfation. In addition to their reactivity with GlyCAM-1 and **CD34**, both MECA 79 and LEC-IgG recognize an independent molecule of approx 200 kD in a sulfate-dependent manner. Thus, this molecule, which we designate Sgp200, is an additional ligand for L-selectin.



File 1:ERIC 1966-1999/Oct  
(c) format only 1999 The Dialog Corporation  
\*File 1: File has been reloaded. See HELP NEWS 1.  
Limits of /ED and /EJ currently not working.

Set	Items	Description
---	-----	-----

? b 410

>>>'IALOG' not recognized as set or accession number  
? set hi ;set hi

15jan00	14:29:45	User208760	Session D1416.1
	\$0.35	0.100	DialUnits File1
\$0.35	Estimated cost File1		
\$0.05	TYMNET		
\$0.40	Estimated cost this search		
\$0.40	Estimated total session cost	0.100	DialUnits

File 410:Chronolog(R) 1981-1999 Nov/Dec  
(c) 1999 The Dialog Corporation plc

Set	Items	Description
---	-----	-----

?  
HILIGHT set on as ''  
**HILIGHT set on as ''**  
? begin 652,653,654

15jan00	14:29:59	User208760	Session D1416.2
	\$0.00	0.049	DialUnits File410
\$0.00	Estimated cost File410		
\$0.01	TYMNET		
\$0.01	Estimated cost this search		
\$0.41	Estimated total session cost	0.149	DialUnits

SYSTEM:OS - DIALOG OneSearch  
File 652:US Patents Fulltext 1971-1979  
(c) format only 2000 The Dialog Corp.  
\*File 652: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.  
File 653:US Pat.Fulltext 1980-1989  
(c) format only 2000 Knight-Ridder Info  
\*File 653: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.  
File 654:US Pat.Full. 1990-2000/Jan 11  
(c) format only 2000 The Dialog Corp.  
\*File 654: Reassignment data current through 12/06/1999 recordings.  
Reexamination, extension, expiration, reinstatement updated weekly.

Set	Items	Description
---	-----	-----

? s (cd34) (30n) (l(w)selectin)

	492	CD34
1060514	L	
	620	SELECTIN
S1	13	(CD34) (30N) (L(W) SELECTIN)

? t s1/3/all

1/3/1 (Item 1 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03050922

Utility

AGONIST ANTIBODIES AGAINST THE FLK2/FLT3 RECEPTOR AND USES THEREOF

PATENT NO.: 5,997,865  
ISSUED: December 07, 1999 (19991207)  
INVENTOR(s): Bennett, Brian D., 460 Point San Bruno Boulevard, South San Francisco, CA (California), US (United States of America), 94080  
Broz, Susan D., 460 Point San Bruno Boulevard, South San Francisco, CA (California), US (United States of America), 94080  
Matthews, William, 460 Point San Bruno Boulevard, South San Francisco, CA (California), US (United States of America), 94080  
Zeigler, Francis C., 460 Point San Bruno Boulevard, South San Francisco, CA (California), US (United States of America), 94080  
[Assignee Code(s): 68000]  
APPL. NO.: 8-434,878  
FILED: May 04, 1995 (19950504)

This is a divisional of application Ser. No. 08-222,299 filed on Apr. 4, 1994 now patented, U.S. Pat No. 5,635,388 which application is incorporated herein by reference and to which application priority is claimed under 35 USC section 120.

FULL TEXT: 2161 lines

1/3/2 (Item 2 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03037991

Utility

INHIBITION OF SELECTIN BINDING

PATENT NO.: 5,985,852  
ISSUED: November 16, 1999 (19991116)  
INVENTOR(s): Nagy, Jon O., Rodeo, CA (California), US (United States of America)  
Spevak, Wayne R., Albany, CA (California), US (United States of America)  
Dasgupta, Falguni, New Delhi, IN (India)  
Bertozzi, Caroline, Albany, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 9-250,999  
FILED: February 16, 1999 (19990216)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of pending U.S. patent application Ser. No. 08-807,428, filed Feb. 28, 1997, which claims priority benefit of U.S. provisional application No. 60-012,894, filed Mar. 1, 1996, both of which are hereby incorporated herein by reference in their entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FULL TEXT: 2032 lines

1/3/3 (Item 3 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03028669

Utility

SULFATED DISACCHARIDE INHIBITORS OF SELECTINS, METHODS FOR SYNTHESIS AND THERAPEUTIC USE

PATENT NO.: 5,977,080  
ISSUED: November 02, 1999 (19991102)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Bertozzi, Carolyn, Berkeley, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 9-4,598  
FILED: January 08, 1998 (19980108)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 08-518,381 filed Aug. 23, 1995 and now issued as U.S. Pat. No. 5,783,693, the disclosure of which is herein incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made in part with Government support under grant number GM-23547 awarded by the National Institute of Health. The Government may have certain rights in this application.

FULL TEXT: 1170 lines

1/3/4 (Item 4 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03016320

Utility

SYNTHETIC MULTIVALENT SLE.SUP.X CONTAINING POLYLACTOSAMINES AND METHODS FOR USE

PATENT NO.: 5,965,544  
ISSUED: October 12, 1999 (19991012)  
INVENTOR(s): Renkonen, Ossi, Espoo, FI (Finland)  
Renkonen, Risto, Espoo, FI (Finland)  
ASSIGNEE(s): Glycim Oy, (A Non-U.S. Company or Corporation), Espoo, FI (Finland)  
APPL. NO.: 8-722,573  
FILED: September 27, 1996 (19960927)

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to the earlier-filed U.S. Provisional Application Ser. Nos. 60-007,867, filed Dec. 1, 1995, and 60-004,623, filed Sep. 29, 1995.

FULL TEXT: 2420 lines

1/3/5 (Item 5 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

03012764

Utility  
INHIBITION OF SELECTIN BINDING

PATENT NO.: 5,962,422  
ISSUED: October 05, 1999 (19991005)  
INVENTOR(s): Nagy, Jon O., Rodeo, CA (California), US (United States of America)  
Spevak, Wayne R., Albany, CA (California), US (United States of America)  
Dasgupta, Falguni, New Delhi, IN (India)  
Bertozzi, Carolyn, Albany, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-807,428  
FILED: February 28, 1997 (19970228)

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority benefit of U.S. provisional application No. 60-012,894, filed Mar. 1, 1996, pending, which is hereby incorporated herein by reference in its entirety.

#### STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FULL TEXT: 2061 lines

1/3/6 (Item 6 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02972981

Utility  
TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR

PATENT NO.: 5,925,349  
ISSUED: July 20, 1999 (19990720)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States

of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-916,766  
FILED: August 19, 1997 (19970819)

#### CROSS-REFERENCES

"This application is a divisional of U.S. patent application Ser. No. 08-496,857, filed Jun. 30, 1995, now U.S. Pat. No. 5,695,752, which application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned", which is a continuation-in-part of our earlier filed applications Ser. No. 07-943,817 filed Sep. 11, 1992, now abandoned, and Ser. No. 08-155,947 filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference in their entirety, and to which applications we claim priority under 35 USC selection 120.

#### GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1523 lines

1/3/7 (Item 7 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02956770

Utility  
HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

PATENT NO.: 5,910,574  
ISSUED: June 08, 1999 (19990608)  
INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)  
Shelton, David L., Pacifica, CA (California), US (United States of America)  
Urfer, Roman, Pacifica, CA (California), US (United States of America)  
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)  
[Assignee Code(s): 7579]  
APPL. NO.: 8-457,880  
FILED: May 31, 1995 (19950531)

This is a continuation of application(s) Ser. No. 08-286,846 filed on Aug. 5, 1994 which is a continuation in part of application Ser. No. 08-215,139, filed Mar. 18, 1994, now abandoned which applications are incorporated herein by reference and to which application(s) priority is claimed under 35 USC selection 120.

FULL TEXT: 4335 lines

1/3/8 (Item 8 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02918917

Utility  
HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

PATENT NO.: 5,877,016  
ISSUED: March 02, 1999 (19990302)

INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)  
Shelton, David L., Pacifica, CA (California), US (United States of America)  
Urfer, Roman, Pacifica, CA (California), US (United States of America)  
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)  
[Assignee Code(s): 7579]  
APPL. NO.: 8-286,846  
FILED: August 05, 1994 (19940805)

This application is a continuation-in-part of copending application Serial No. 08-215,139 filed 18 Mar. 1994, now abandoned.  
FULL TEXT: 4307 lines

1/3/9 (Item 9 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02881960

Utility  
HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

PATENT NO.: 5,844,092  
ISSUED: December 01, 1998 (19981201)  
INVENTOR(s): Presta, Leonard G., San Francisco, CA (California), US (United States of America)  
Shelton, David L., Pacifica, CA (California), US (United States of America)  
Urfer, Roman, Pacifica, CA (California), US (United States of America)  
ASSIGNEE(s): Genentech, Inc , (A U.S. Company or Corporation), S. San Francisco, CA (California), US (United States of America)  
[Assignee Code(s): 7579]  
APPL. NO.: 8-359,705  
FILED: December 20, 1994 (19941220)

This application is a continuation in part of copending application Ser. No. 08-286,846, filed 5 Aug., 1994, which is a continuation-in-part of application Ser. No. 08-215,139 filed 18 Mar., 1994, now abandoned.

FULL TEXT: 4366 lines

1/3/10 (Item 10 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02816930

Utility  
METHODS FOR SYNTHESIZING SULFATED DISACCHARIDE INHIBITORS OF SELECTINS  
[Sulfation lactose with sulfur trioxide]

PATENT NO.: 5,783,693  
ISSUED: July 21, 1998 (19980721)  
INVENTOR(s): Bertozzi, Carolyn, San Francisco, CA (California), US (United States of America)  
Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-518,381

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application Ser. No. 08-432,849, filed May 2, 1995, now U.S. Pat. No. 5,489,578, which is a continuation of patent application Ser. No. 08-155,947, filed Nov. 10, 1993 (now abandoned), both of which applications are incorporated herein by reference and to which applications we claim priority under 35 USC selection 120.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made in part with Government support under grant number GM-23547 awarded by the National Institute of Health. The Government may have certain rights in this application.

FULL TEXT: 1155 lines

1/3/11 (Item 11 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721611

Utility  
TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES  
AND/OR SULFATION INHIBITOR

PATENT NO.: 5,695,752  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-496,857  
FILED: June 30, 1995 (19950630)

CROSS-REFERENCES

This application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned, which is a continuation-in-part of earlier filed U.S. application Ser. No. 07-943,817, filed Sep. 11, 1992, now abandoned, and earlier filed U.S. application Ser. No. 08-155,947, filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference and to which applications we claim priority under 35 U.S.C. selection 120.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1641 lines

1/3/12 (Item 12 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02680411

Utility

MOCARHAGIN, A COBRA VENOM PROTEASE, AND THERAPEUTIC USES THEREOF  
[Antiinflammatory agents]

PATENT NO.: 5,659,018  
ISSUED: August 19, 1997 (19970819)  
INVENTOR(s): Berndt, Michael C., Mt Eliza, AU (Australia)  
Dunlop, Lindsay, Kirwan, AU (Australia)  
Andrews, Robert, Hampton, AU (Australia)  
DeLuca, Mariagrazia, Dandenong North, AU (Australia)  
ASSIGNEE(s): Genetics Institute, Inc, (A U.S. Company or Corporation),  
Cambridge, MA (Massachusetts), US (United States of America)  
[Assignee Code(s): 12457]  
APPL. NO.: 8-520,977  
FILED: August 01, 1995 (19950801)  
FULL TEXT: 838 lines

1/3/13 (Item 13 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02495999

Utility

SULFATED LIGANDS FOR L-SELECTIN AND METHODS OF TREATING INFLAMMATION  
[Antiinflammatory agents]

PATENT NO.: 5,489,578  
ISSUED: February 06, 1996 (19960206)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United  
States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United  
States of America)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company  
or Corporation), Oakland, CA (California), US (United States  
of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-432,849  
FILED: May 02, 1996 (19960502)

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.  
08-155,947 filed Nov. 19, 1993, now abandoned, which we claim priority  
under 35 USC selection 120 and which is incorporated herein by reference.

GOVERNMENT RIGHTS

The United States Government may have certain rights in this application  
pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1822 lines  
? t sl/k/all

1/K/1 (Item 1 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

OTHER REFERENCES

... in humans can be distinguished from colony-forming cells by expression  
of the CD33 and CD34 antigens and light scatter properties" Journal  
of Experimental Medicine 169:1721-1731 (1989).



Baumhueter et al., "Binding of **L-selectin** to the vascular sialomucin **CD34**" Science 262:436-438 (1993).

Berenson et al., "Antigen **CD34** + Marrow Cells Engraft Lethally Irradiated Baboons" J. Clin. Invest. 81:951-955 (1988).

Better and...

1/K/2 (Item 2 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... 1) (Moore et al., J. Cell Biol. 128:661, 1995). The natural ligands identified for **L-selectin** is neither of these, but include other glycoproteins with the designations GlyCAM-1, **CD34**, and MAdCAM-1.

The binding specificity indicates that at least two of the three selectins...

1/K/3 (Item 3 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... Rosen & Bertozzi (1994) Curr. Op. Cell Biol. 6:663-673). Three HEV-associated ligands for **L-selectin** have previously been identified as mucin-like glycoproteins: GlyCAM-1 (Lasky et al. (1992) Cell 69:927-938), **CD34** (Baumhueter et al. (1993) Science 262:436-438) and MAdCAM-1 (Briskin et al. (1993...

1/K/4 (Item 4 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

... Arbones, M. L. et al., "Lymphocyte Homing and Leukocyte Rolling and Migration Are Impaired in **L-Selectin**-Deficient Mice," Immunity 1(4):247-260 (Jul. 1994).

Baumhueter, S. et al., "Binding of **L-Selectin** to the Vascular Sialomucin **CD34**," Science 262:436-438 (Oct. 1993).

Bertozzi, C. R., "Cracking the carbohydrate code for selectin...

... Ley, K. et al., Blood 77:2553-2555 (1991)), both of which are impaired in **L-selectin** deficient mice (Arbones, M. L. et al., Immunity 1:247-260 (1994)).

Three glycoprotein ligands for **L-selectin** are currently known: GlyCAM-1, **CD34** and MAdCAM-1. The exact structures of the biological ligands of **L-selectin** are not yet known, but the principal carbohydrate epitopes share some structural features. They are...

1/K/5 (Item 5 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... 1) (Moore et al., J. Cell Biol. 128:661, 1995). The natural ligands identified for **L-selectin** is neither of these, but include other glycoproteins with the designations GlyCAM-1, **CD34**, and MAdCAM-1.

The binding specificity indicates that at least two of the three selectins...

1/K/6 (Item 6 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...the ligand. We found that chlorates act to inhibit biochemical sulfation of GlyCAM-1 and CD34/Sgp90 and thereby prevent their ability to bind to **L-selectin**. Second, we endeavored to identify the exact sulfate substitutions on the carbohydrates of a natural ligand for **L-selectin** (i.e. GlyCAM-1). We showed that galactose-6 sulfate and N-acetylglucosamine-6-sulfate... independent of its overall sialylation and fucosylation) plays an essential role in ligand activity for **L-selectin** (Imai, Y., Lasky, L. A., and Rosen, S. D., Nature, 361:555-557 (1993)). The importance of sulfation also holds for Sgp90/CD34. There are other examples of biologically significant recognition determinants that are defined by sulfate modifications...or equal to 90) incorporation of sup 35 S-SO sub 4 into GlyCAM and CD34 and completely eliminated binding to **L-selectin**. Binding of GlyCAM to a sialic acid specific lectin (Limax agglutinin) or to a fucose ...

... chlorate did not affect the rate of synthesis of the protein core of GlyCAM or CD34. Taken together, these results establish that sulfate is very important for the interaction of GlyCAM and CD34 with **L-selectin**. In that sialyl-Lewis X (i.e., sLe sup x) possesses ligand activity for **L-selectin** we have been able to deduce that the key carbohydrate chains of GlyCAM involve a...for sulfate addition, we concluded that the critical sulfates must be on the carbohydrate chains. CD34/Sgp90 is also a sulfated ligand of **L-selectin**. When the sulfation of this molecule was inhibited by chlorate treatment its ability to interact with **L-selectin** was also drastically inhibited.

#### Determination of the Sulfated Oligosaccharides of GlyCAM-1

As reviewed above, the sulfation of GlyCAM-1 and CD34/Sgp90 (two endothelial-associated ligands) are required for their interaction with **L-selectin**. In that sulfatases are specific (i.e., remove sulfation from a specific position) it was...

1/K/7 (Item 7 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin** ligands, GlyCAM-1 and CD34, which were identified and purified using an **L-selectin** -IgG affinity column (Imai et al., J. Cell. Biol. 113, 1213-1221 (1991); Watson et...

1/K/8 (Item 8 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin** ligands, GlyCAM-1 and CD34, which were identified and purified using an **L-selectin** -IgG affinity column (Imai et al., J. Cell. Biol. 113, 1213-1221 (1991); Watson et...

1/K/9 (Item 9 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... species, and for purifying such ligands. Ligands identified so far by this approach include two **L-selectin** ligands, GlyCAM-1 and CD34, which were identified and purified using an **L-**

**selectin** -IgG affinity column (Imai et al., J. Cell. Biol. 113, 1213-1221 (1991); Watson et...

1/K/10 (Item 10 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... Rosen & Bertozzi (1994) Curr. Op. Cell Biol. 6:663-673). Three HEV-associated ligands for **L-selectin** have previously been identified as mucin-like glycoproteins: GlyCAM-1 (Lasky et al. (1992) Cell 69:927-938 ), **CD34**(Baumheuter et al. (1993) Science 262:436-438) and MAdCAM-1 (Briskin et al. (1993...

1/K/11 (Item 11 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...the ligand. We found that chlorates act to inhibit biochemical sulfation of GlyCAM-1 and **CD34**/Sgp90 and thereby prevent their ability to bind to **L-selectin**. Second, we endeavored to identify the exact sulfate substitutions on the carbohydrates of a natural ligand for **L-selectin** (i.e. GlyCAM-1). We showed that galactose-6 sulfate and N-acetylglucosamine-6-sulfate... independent of its overall sialylation and fucosylation) plays an essential role in ligand activity for **L-selectin** (Imai, Y., Lasky, L. A., and Rosen, S. D., Nature, 361:555-557 (1993)). The importance of sulfation also holds for Sgp90/**CD34** . There are other examples of biologically significant recognition determinants that are defined by sulfate modifications...or equal to 90%) incorporation of sup 35 S-SO sub 4 into GlyCAM and **CD34** and completely eliminated binding to **L-selectin**. Binding of GlyCAM to a sialic acid specific lectin (Limax agglutinin) or to a fucose ...

... chlorate did not affect the rate of synthesis of the protein core of GlyCAM or **CD34**. Taken together, these results establish that sulfate is very important for the interaction of GlyCAM and **CD34** with **L-selectin** . In that sialyl-Lewis X (i.e., sLe sup x) possesses ligand activity for **L-selectin** we have been able to deduce that the key carbohydrate chains of GlyCAM involve a...for sulfate addition, we concluded that the critical sulfates must be on the carbohydrate chains. **CD34**/Sgp90 is also a sulfated ligand of **L-selectin**. When the sulfation of this molecule was inhibited by chlorate treatment its ability to interact with **L-selectin** was also drastically inhibited.

#### Determination of the Sulfated Oligosaccharides of GlyCAM-1

As reviewed above, the sulfation of GlyCAM-1 and **CD34**/Sgp90 (two endothelial-associated ligands) are required for their interaction with **L-selectin** . In that sulfatases are specific (i.e., remove sulfation from a specific position) it was...

1/K/12 (Item 12 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... a wide variety of sialomucin structures if they co-express the sialyl-Lewis x structure. **L-selectin** binds to a number of different counter-receptors, GLYCAM-1, MAdCAM-1 and **CD34**, which like PSGL-1, are also sialomucins. A major question currently unresolved is what determines selectin specificity in the recognition of specific counter-receptor structures. P-, E- and **L-selectin** are 60-70% homologous in their N-terminal, 118-amino acid lectin motifs and each...

1/K/13 (Item 13 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... has been given the designation GlyCAM-1. Sgp90 is a HEV-specific glyco-form of CD34. Sialic acid on both Sgp50 and Sgp90 is required for their interaction with L-selectin. Several fortuitous carbohydrate-based inhibitors of L-selectin such as fucoidin and sulfatide are sulfated. Sulfate is required (but not sufficient) for binding...

? s cd34(40n) (inhibit? or suppress? or antagoni? or decreas?) (30n) (inflamm?)

492	CD34
290327	INHIBIT?
143735	SUPPRESS?
24963	ANTAGONI?
670962	DECREAS?
36013	INFLAMM?
S2	6 CD34(40N) (INHIBIT? OR SUPPRESS? OR ANTAGONI? OR DECREAS?) (30N) (INFLAMM?)

? t s2/3/all

2/3/1 (Item 1 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02972981

Utility  
TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES  
AND/OR SULFATION INHIBITOR

PATENT NO.: 5,925,349  
ISSUED: July 20, 1999 (19990720)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents Of The University Of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-916,766  
FILED: August 19, 1997 (19970819)

#### CROSS-REFERENCES

"This application is a divisional of U.S. patent application Ser. No. 08-496,857, filed Jun. 30, 1995, now U.S. Pat. No. 5,695,752, which application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned", which is a continuation-in-part of our earlier filed applications Ser. No. 07-943,817 filed Sep. 11, 1992, now abandoned, and Ser. No. 08-155,947 filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference in their entirety, and to which applications we claim priority under 35 USC selection 120.

#### GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1523 lines

2/3/2 (Item 2 from file: 654)  
DIALOG(R)File 654:US Pat.Full.

02842782

Utility

METHOD FOR TREATMENT OF PURULENT INFLAMMATORY DISEASES

[Administering glutamic acid, tryptophan dipeptide]

PATENT NO.: 5,807,830

ISSUED: September 15, 1998 (19980915)

INVENTOR(s): Morozov, Vyacheslav G., St. Petersburg, RU (Russian Federation)  
Khavinson, Vladimir Kh., St. Petersburg, RU (Russian Federation)

ASSIGNEE(s): Cytoven J V , (A U.S. Company or Corporation), Kirkland, WA (Washington), US (United States of America)  
[Assignee Code(s): 39334]

APPL. NO.: 8-452,061

FILED: May 26, 1995 (19950526)

PRIORITY: 4352833, SU (USSR), December 30, 1987 (19871230)

This application is a continuation-in-part of application Ser. No. 337,341 filed Nov. 10, 1994, now U.S. Pat. No. 5,538,951 and a continuation-in-part of Ser. No. 08-278,463, filed Jul. 21, 1994 (abandoned), which is a continuation-in-part of application Ser. No. 08-257,495, filed Jun. 7, 1994 (abandoned), which is a continuation of application Ser. No. 07-783,518, filed Oct. 28, 1991 (abandoned), which is a continuation-in-part of Ser. No. 07-678,129, filed Apr. 1, 1991 (abandoned), which is a continuation-in-part of application Ser. No. 07-415,283, filed Aug. 30, 1989 (abandoned), which is a United States national stage application of PCT-SU88-00255, filed Dec. 14, 1988, which claims the benefit of the filing date of Soviet application SU 4,352,833, filed Dec. 30, 1987. This application also claims the benefit of the filing date of U.S. patent application Ser. No. 08-337,341, filed Nov. 10, 1994, now issued as U.S. Pat. No. 5,538,951, whose specification is identical to Ser. No. 07-415,283. All of the above applications are hereby incorporated by reference.

FULL TEXT: 10218 lines

2/3/3 (Item 3 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02842698

Utility

USE OF INTERFERON .GAMMA. FOR THE INHIBITION OF PROLIFERATION AND DIFFERENTIATION OF PRIMITIVE HEMATOPOIETIC PROGENITOR CELLS

[Incubation; separation of bone marrow and tumor cells]

PATENT NO.: 5,807,744

ISSUED: September 15, 1998 (19980915)

INVENTOR(s): Berneman, Zwi, Antwerp, BE (Belgium)  
Van Bockstaele, Dirk, Edegem, BE (Belgium)  
Snoeck, Hans-Willem, Antwerp, BE (Belgium)

ASSIGNEE(s): Boehringer Mannheim GmbH, (A Non-U.S. Company or Corporation), Mannheim, DE (Germany)  
[Assignee Code(s): 10203]

APPL. NO.: 8-514,897

FILED: August 14, 1995 (19950814)

PRIORITY: 94112688.0, EP (European Patent Office), August 13, 1994 (19940813)

FULL TEXT: 923 lines

2/3/4 (Item 4 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02803471

Utility

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF: SYSTEMIC TOXICITY

[ Administering glutamic acid-tryptophan dipeptide to stimulate binding function of T-lymphocytes]

PATENT NO.: 5,770,576

ISSUED: June 23, 1998 (19980623)

INVENTOR(s): Morozov, Vyacheslav G., St. Petersburg, RU (Russian Federation)  
Khavinson, Vladimir Kh., St. Petersburg, RU (Russian Federation)

ASSIGNEE(s): Cytran, Inc , (A U.S. Company or Corporation), Kirkland, WA (Washington), US (United States of America)  
[Assignee Code(s): 45946]

EXTRA INFO: Assignment transaction [Reassigned], recorded September 1, 1998 (19980901)

APPL. NO.: 8-452,077

FILED: May 26, 1995 (19950526)

This application is a continuation-in-part of application Ser. No 08-278,463 filed Jul. 21, 1994 (abandoned) which is a continuation-in-part of application Ser. No. 08-257,495 filed Jun. 7, 1994 (abandoned) which is a continuation of Ser. No 07-783,518 filed Oct. 28, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-678,129 filed Apr. 1, 1991 (abandoned) which is a continuation-in-part of Ser. No. 07-415,283 filed Aug. 30, 1989 (abandoned). Application Ser. No. 07-415,283 is a national stage application of PCT-SU88,00255 filed Dec. 14, 1988 which claims a priority date from SU Patent 4,352,833 filed Dec. 30, 1987. Application Ser. No. 08-337,341 filed Nov. 10, 1994 is a divisional of Ser. No. 07-415,283 and issued as U.S. Pat. No. 5,538,951. All the above patent applications are hereby incorporated by reference.

FULL TEXT: 10093 lines

2/3/5 (Item 5 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) format only 2000 The Dialog Corp. All rts. reserv.

02799389

Utility

SYSTEMIC GENE TREATMENT OF CONNECTIVE TISSUE DISEASES WITH IRAP-1

[ Infecting bone marrow cells with recombinant retroviral expression vector that contains a polynucleotide sequence coding a biologically active interleukin receptor antagonist protein, injecting into host; antiinflammatory agents]

PATENT NO.: 5,766,585

ISSUED: June 16, 1998 (19980616)

INVENTOR(s): Evans, Christopher H., Pittsburgh, PA (Pennsylvania), US (United States of America)  
Robbins, Paul D., Pittsburgh, PA (Pennsylvania), US (United States of America)

ASSIGNEE(s): University of Pittsburgh of the Commonwealth System of Higher Education, (A U.S. Company or Corporation), Pittsburgh, PA (Pennsylvania), US (United States of America)  
[Assignee Code(s): 66208]

APPL. NO.: 8-697,180

FILED: August 20, 1996 (19960820)

This application is a continuation of application Ser. No. 08-167,642, filed Dec. 14, 1993, now abandoned.

FULL TEXT: 1740 lines

2/3/6 (Item 6 from file: 654)  
DIALOG(R)File 654:US Pat.Full.  
(c) format only 2000 The Dialog Corp. All rts. reserv.

02721611

Utility

TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES  
AND/OR SULFATION INHIBITOR

PATENT NO.: 5,695,752  
ISSUED: December 09, 1997 (19971209)  
INVENTOR(s): Rosen, Steven D., San Francisco, CA (California), US (United  
States of America)  
Hemmerich, Stefan, San Francisco, CA (California), US (United  
States of America)  
Imai, Yasuyuki, Tokyo, JP (Japan)  
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company  
or Corporation), Oakland, CA (California), US (United States  
of America)  
[Assignee Code(s): 13234]  
APPL. NO.: 8-496,857  
FILED: June 30, 1995 (19950630)

#### CROSS-REFERENCES

This application is a continuation of U.S. patent application Ser. No. 08-214,947, filed Mar. 16, 1994, now abandoned, which is a continuation-in-part of earlier filed U.S. application Ser. No. 07-943,817, filed Sep. 11, 1992, now abandoned, and earlier filed U.S. application Ser. No. 08-155,947, filed Nov. 19, 1993, now abandoned, all of which applications are incorporated herein by reference and to which applications we claim priority under 35 U.S.C. selection 120.

#### GOVERNMENT RIGHTS

The United States Government may have certain rights in this application pursuant to Grant No. GM-23547 awarded by the National Institute of Health.

FULL TEXT: 1641 lines  
? t s2/k/all

2/K/1 (Item 1 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... receptor. Impairing such binding interrupts the biochemical chain of events which, in excess, leads to **inflammation**. By interrelating such facts we deduced that it would be possible to alleviate and/or prevent **inflammation** in two ways. First, we endeavored to find a compound which would **inhibit** sulfation, i.e. **inhibit** the addition of a sulfate moiety onto a natural selectin ligand--thereby preventing complete formation of the ligand. We found that chlorates act to **inhibit** biochemical sulfation o GlyCAM-1 and **CD34/Sgp90** and thereby prevent their ability to bind to L-selectin.

2/K/2 (Item 2 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... number of neutrophils in a measured volume of a tissue infiltrate in response to an **inflammatory** agent; and/or (xiii) increasing the percentage of phagocytically active cells in a neutrophil infiltrate... invention find use during in vitro maintenance and expansion of bone

marrow, peripheral blood leukocytes, **CD34** sup + lymphocytes, and other immune cells, such as may occur prior to autologous or allogenic...

2/K/3 (Item 3 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...mature human committed erythroid and myeloid progenitor cells (Snoeck et al. (48)). IFN- gamma probably **inhibits** apoptosis of progenitor cells. However, due to the very limited number of **CD34++CD38-** cells which could be isolated from a bone marrow ...by either demonstrating a DNA-ladder or by flow cytometry.

Since IFN- gamma is an **inflammatory** cytokine which at the same time **inhibits** proliferation and cell death of very primitive progenitor cells and stimulates proliferation of more mature progenitors, it might, in situations of increased demand for blood cells such as infection, **inflammation** and blood loss, stimulate the expansion of committed progenitor cells and their proliferation and differentiation...

2/K/4 (Item 4 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... number of neutrophils in a measured volume of a tissue infiltrate in response to an **inflammatory** agent; and/or (xiii) increasing the percentage of phagocytically active cells in a neutrophil infiltrate... invention find use during in vitro maintenance and expansion of bone marrow, peripheral blood leukocytes, **CD34** sup + lymphocytes, and other immune cells, such as may occur prior to autologous or allogenic...

... individual with a diagnosed autoimmune disease in an amount and for a time sufficient to **decrease** one or more laboratory indicia of the disease state in the patient. Representative examples of...

2/K/5 (Item 5 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... an anti-oxidant, such as superoxide dismutase, or a biologically active fragment thereof, and an **inhibitor** of nitric oxide synthase, or biologically active fragments thereof; (9) a nucleic ...fragment encoding constituents of the extracellular matrix, such as collagen.

Nucleic acid sequences encoding anti-**inflammatory** therapeutic gene products or biologically active fragments thereof which **decrease** local concentration of IL-1 and/or TGF-1 are preferred in the treatment of ...

... retroviral mediated infection of either hematopoietic stem cell populations such as bone marrow cells or **CD34+** cell populations.

#### 5.4.12. SYSTEMIC TREATMENT OF PAGET'S DISEASE

Paget's disease (Osteitis... an anti-oxidant, such as superoxide dismutase, or a biologically active fragment thereof, and an **inhibitor** of nitric oxide synthase, or biologically active fragments thereof; (9) a nucleic acid sequence encoding...

... fragment encoding constituents of the extracellular matrix, such as collagen.

Nucleic acid sequences encoding anti-**inflammatory** therapeutic gene products or biologically active fragments thereof, systemically delivered by way of retroviral mediated infection of either hematopoietic stem cell populations such as bone marrow cells or **CD34+** cell populations are



preferred in the treatment of Paget's disease.

#### 5.4.13. SYSTEMIC TREATMENT OF INFLAMMATORY BOWEL DISEASE

**Inflammatory** bowel disease is a generic term relating to a group of chronic **inflammatory** disorders of unknown etiology involving the gastrointestinal tract. Chronic **inflammatory** bowel disease is divided into two major groups, ulcerative colitis and Crohn's disease. While the cause of **inflammatory** bowel disease is unknown, possible etiologic factors include infectious, immunologic, familial or psychological factors. Secondary...

... said vector such that said bone marrow cells express said biologically active interleukin-1 receptor **antagonist** protein;

injecting said infected bone marrow cells into said host such that systemic transfer and expression of said biologically active interleukin-1 receptor **antagonist** protein occurs within said host;

wherein said transfer and expression within said host reduces **inflammation** resulting from rheumatoid arthritis.

2. The method of claim 1 wherein said bone marrow cells comprise **CD34** sup + leukocytes.

3. The method of claim 1 wherein said retroviral vector is MFG-IRAP.

2/K/6 (Item 6 from file: 654)

DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... receptor. Impairing such binding interrupts the biochemical chain of events which, in excess, leads to **inflammation**. By interrelating such facts we deduced that it would be possible to alleviate and/or prevent **inflammation** in two ways. First, we endeavored to find a compound which would **inhibit** sulfation, i.e. **inhibit** the addition of a sulfate moiety onto a natural selectin ligand--thereby preventing complete formation of the ligand. We found that chlorates act to **inhibit** biochemical sulfation of GlyCAM-1 and **CD34**/Sgp90 and thereby prevent their ability to bind to L-selectin.